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CHAPTER 1 
1. Introduction 
1.1. Cytochrome P450 Enzymes 
Cytochrome P450 (CYP, P450) enzymes were initially named for the change in 
absorbance found from the reduced form of the enzyme in the presence of CO which 
provided an absorbance maxima of 450 nm (1). Initially, P450 enzymes were investigated 
and purified for roles played in drug metabolism, especially in the liver (2-4). More recently 
with the rapid expansion of genomic data, there has been an initiative to follow a naming 
convention. The nomenclature guidelines for P450 families share at least 40% amino acid 
identity, while members of subfamilies must share at least 55% amino acid identity (i.e., 
P450 3A4: 3 (family) A (subfamily) 4 (enzyme) (5). Additionally, when referring to the P450 
gene, the name would be italicized (i.e., CYP3A4) and the protein name is not (i.e., P450 
3A4). Capitalization also may denote species-specific P450 enzymes (i.e., human P450 
4A11, mouse P450 4a12, rat P450 4A12).  
P450 enzymes are localized to either the endoplasmic reticulum (ER) or the 
mitochondria. The endoplasmic reticulum  is a site of protein translation, posttranslational 
processing, and small molecule metabolism (6). Posttranslational processing includes 
glycosylation of proteins for sorting, disulfide bond formation, and specific proteolytic 
cleavages. The ER lumen is an oxidizing environment that aids in the production of 
disulfide bonds, which is maintained at a homeostatic level by both small molecules 
(ascorbate and glutathione (GSH)) and proteins (protein disulfide isomerases) (7,8). The 
cytosolic side of the ER remains a reducing environment to preserve the normal function 
of integral ER proteins (Figure 1).  
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P450 enzymes are found in the cytoplasmic side of the ER and are most well-
known for the ability to metabolize xenobiotics and important endogenous substrates (e.g., 
steroids and vitamins) (9). These proteins have been of interest in the pharmaceutical 
industry since their initial discovery, and enzymes mainly in P450 Subfamilies 1A, 2C, 2D, 
and 3A are involved in the metabolism and clearance of a large majority of small molecule 
drugs currently approved for clinical use in humans (9). P450 regulation involves genetic 
and epigenetic aspects, as well as transcriptional regulation by both endogenous and 
exogenous factors (10). Post-transcriptional mRNA processing is also known and has also 
been found to be highly controlled (10).  
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Figure 1. The Lumen of the Endoplasmic Reticulum. Oxidizing environment inside the 
lumen of the endoplasmic reticulum maintained at homeostasis by various small 
molecules and proteins. During the protein folding process, production of reactive oxygen 
species (ROS) by possible surrounding sources, such as NADPH oxidase 4 (Nox4), 
NADPH-P450 reductase (NPR), and GSH topologies, along with their functions in the 
outer ER environment. NADPH, Nicotinamide adenine dinucleotide phosphate; G6P, 
glucose-6-phosphate; 6PG, 6-phospho gluconate; Nox4, NADPH oxidase 4; GSH, 
glutathione; GSSG, glutathione disulfide; ERO1, ER oxidoreductin 1; PDI, protein disulfide 
isomerase. CYP; Cytochrome p450. Adapted from (11)  
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P450s play two major biological roles: (1) xenobiotic metabolism, with the goal 
being a decrease in the hydrophobicity of compound for ease of excretion and for further 
metabolism by enzymes such as sulfotransferases and UDP-glucuronyltransferases 
(UGT), and (2) biosynthesis of bioactive molecules including steroids, vitamins, and 
oxidized fatty acids (Table 1) (9). A subset of the latter role is the activation, deactivation, 
and turnover of bioactive molecules, e.g. vitamins A and D (12,13). Also, a small subset 
of P450s are still considered “orphan” enzymes which have unknown function or 
substrates. Many diseases are associated with specific P450 variants, and other diseases 
result from a lack of genes or the substitution of functionally inactive mutants (14-16). 
The various P450s are diverse despite sharing common structural features. P450s 
are also some of the most promiscuous enzymes, with human P450 3A4 having 
thousands of reported substrates (17,18). Plants have greater numbers of P450-encoded 
genes than any other kingdom of organisms (e.g., wheat has 1476). These are extensively 
involved in the synthesis of secondary metabolites and defense molecules (19). 
Prokaryotic P450s synthesize important secondary metabolites such as antibiotics and 
have also been used as model enzymes for the study of all aspects of the general P450 
catalytic cycle (20). The use of prokaryotic P450s to catalyze diverse chemical reactions 
that are difficult to perform synthetically has proved to be promising as well (21). This 
includes the use of H2O2 and oxygen compounds as oxygen surrogates (e.g., peracids, 
hydroperoxides, iodosylbenzene) for chemical reactions (22). This oxidative chemistry has 
implications important to the understanding of P450s in a biological context.  
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Figure 2. The General P450 Catalytic Cycle (from (23) 
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Table 1. Cytochrome P450s with Specific Substrate Classes Highlighted.  
 
  
Steroids Xenobiotics
Fatty 
Acids
Eicosanoids Vitamins
Unknown 
(Orphan)
1B1 1A1 2J2 4F2 2R1 2A7
7A1 1A2 2U1 4F3 24A1 2S1
7B1 2A6 4A11 4F8 26A1 2W1
8B1 2A13 4B11 5A1 26B1 4A22
11A1 2B6 4F11 8A1 26C1 4X1
11B1 2C8 4F12 27B1 4Z1
11B2 2C9 4F22 27C1 20A1
17A1 2C18 4V2
19A1 2C19
21A2 2D6
27A1 2E1
39A1 2F1
46A1 3A4
51A1 3A5
3A7
3A43
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The general reaction scheme for P450-catalyzed reaction are as follows with RH 
as substrate 
RH + NADPH + O2 + H+ → ROH + NADP+ + H2O 
This hydroxylation reaction involves a complex cycle which can be visualized in 
Figure 2. In the resting state, P450s are generally thought to have a water molecule as 
the sixth ligand coordinated to the ferric iron of the heme prosthetic group (Fig. 2, A). Upon 
substrate binding, the water ligand is often displaced, and an electron is donated from a 
redox partner, either cytochrome NADPH-P450 reductase (endoplasmic reticulum) or 
adrenodoxin (mitochondria), oxidizing NAD(P)H and reducing the iron to its ferrous form. 
Ferrous heme can then bind oxygen forming the formal ferric superoxide complex (Fig. 2, 
D). Another electron is supplied from a redox partner producing the P450-peroxo complex 
(Fig. 2, E). This is quickly protonated to form the P450-hydroperoxo complex (Fig. 2, F). 
This complex is protonated which destabilizes the oxygen-oxygen bond, forming 
Compound I ((Fig. 2, G) and water. This highly electrophilic species readily abstracts a 
proton from the substrate leaving a free radical substrate species that facilitates a 
homolytic cleavage reaction with the FeIV- oxygen bond-forming a hydroxylated product 
and ferric heme iron. Water then displaces the product returning the P450 to its resting 
state.  
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Figure 3. Surface Electrostatic Plot of Human P450 2B4. Electrostatic surface of P450 
2B4 shows the central basic residues proposed to be involved in P450-reductase 
binding and a hydrophobic patch that includes V267 and L270 indicated by the dashed 
yellow circle. Red represents acidic residues while blue represents basic residues on the 
surface of P450 2B4.From (24) 
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The interaction of P450 and its redox partners is still not completely understood. 
From a crystal structure of rat NADPH-P450 reductase, it was apparent that there are 
three domains of the protein: the NADPH/flavin-adenine dinucleotide (FAD) binding 
domain in which the FAD moiety accepts electrons from NADPH, a linker domain, and a 
flavin mononucleotide (FMN) domain which interacts with P450s and is involved in 
electron transfer to the heme (25). The reductase is thought to interact with P450s through 
both electrostatic and van der Waals interactions as well as membrane anchoring 
topologies (Fig. 3) (24). Considering that this reductase has to provide electrons to all 
P450s located in the ER and there is not a conserved CPR binding region among P450s, 
the mechanism of interaction and electron transfer is of great interest. 
1.2. P450 Interactions with Hydrogen Peroxide 
1.2.1. Reactions with Iron and H2O2 
Iron reacts readily with molecular oxygen and H2O2 to produce species capable of 
performing a diverse array of oxidation reactions. Known broadly as Fenton reactions (26), 
when this chemistry is uncontrolled it can generate a mixture of nonspecific products with 
organic reactants and is generally undesired in most biochemical systems (27). These are 
generally controlled in vitro by the addition of iron chelating reagents such as EDTA. 
P450s, as well as some other iron-centered enzymes (28), control the reaction of oxygen 
with iron in a stereospecific and regiospecific manner. These enzymes have varying 
efficiencies and are dependent on numerous factors. The iron-oxo reaction also allows for 
action on a varied number of substrates, because a general role in much of xenobiotic 
metabolism is to produce more hydrophilic compounds for facile excretion and also allows 
for so-called “secondary” metabolism of xenobiotics (e.g., sulfation and glucuronidation). 
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Figure 4. P450 Production, Reaction, and Inhibition with H2O2. P450s can produce 
H2O2 in three separate reactions after molecular oxygen binds to the ferrous heme (red 
circle, numbered reactions). H2O2 can also be used as a co-substrate and oxygen donor 
in peroxygenase and peroxidase reactions (green oval). Additionally, H2O2 can inhibit 
catalysis through sulfenylation of the heme-thiolate ligand (blue oval). From (29)  
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1.2.2. H2O2 Production Through Pathway Uncoupling 
Since the report of Gillette et al. (30) on the NADPH-dependent production of H2O2 
in liver microsomes, there has been interest in this area of study. Several years later, a 
stoichiometric anomaly observed between NADPH, oxygen consumption, and product 
formation in liver microsomes (31) was accounted for when H2O2 and H2O production were 
measured as side products in P450 reactions (32,33). H2O2 production, plus the 
generation of superoxide anion by NADPH-P450 reductase (34) and P450 (35), led to the 
hypothesis that P450 induction may be related to hepatic disfunctions such as ethanol-
induced liver damage (36-38). Uncoupling has been proposed to have potentially 
damaging circumstances by contributing to reactive oxygen species (ROS) production and 
to accelerating the aging process (39). 
ROS production can, at least in principle, occur at three intermediate stages during 
the normal P450 catalytic cycle (Fig. 4). The first is directly after molecular oxygen binding 
to the ferrous heme (Fig. 4, Reaction 1, dashed line). This has been described as the ferric 
superoxide complex, FeIII-O2- (40). This state is only 1 kcal mol-1 above the heme resting 
state (FeIII), and the oxygen-iron bond can easily be broken to form superoxide anion (O2•-
) and iron (III) heme (41). The rate of this process (FeII  —> FeIII + O2•–), termed 
autoxidation, is related to the stability of the FeII-O2 complex and varies among P450s 
(42), and the rate of autooxidation is dependent on temperature (43,44). Superoxide is 
quickly dismutated (non-enzymatically) to H2O2. Structural studies with P450cam have 
elucidated a coordination sphere surrounding the heme-thiolate ligand, which reduces the 
sulfur charge and allows for reduction to ferrous heme (45). This hydrogen bonding 
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network appears to fine-tune the positioning and electron donating ability of cysteine sulfur 
(46).  
The second and third stages at which ROS can be produced, following the second 
reduction step, are from the P450 peroxo (FeIII-O-O2-) and hydroperoxo (FeIII-O-OH-) 
complexes (“Compound 0”). The Fe-O bond of the peroxo complex can be broken, and 
the oxygen species can be doubly protonated to form H2O2 (Fig. 4, Reaction 2). In a similar 
fashion, after protonation the hydroperoxo complex can either be further protonated, 
forming Compound I (FeIV=O3+) and H2O, or the Fe-O bond can break, once again forming 
H2O2 (Fig. 4, Reaction 3).  
This uncoupling appears to be dependent on several factors, including pH, 
substrate positioning in the active site, and a disturbed substrate binding pocket. The 
heme thiolate allows for the correct amount of “push” and “pull” of electrons for the 
successful completion of the P450 catalytic cycle (47). Bacterial enzymes generally have 
very high coupling efficiencies for native substrates compared to mammalian P450s 
(Table 2). This difference in coupling efficiency may be due to the number of substrates 
mammalian P450s can accommodate compared to bacterial enzymes.   
ROS generated by P450 from inefficient reaction cycles can, in principle, oxidize 
cellular proteins, lipids, and DNA. This alteration in cellular redox balance can lead to 
signaling involved in antioxidant responses, create an oxidatively stressed environment, 
and potentially lead to disease (48). Evidence has amassed for potential ROS-dependent 
toxicity involving P450s in the CYP Subfamilies 1, 2, 3, and 4 (39,49).  
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P450 Substrate % coupling efficiency Reference 
1A1 Phenacetin 2.5 (50) 
1A2 Methanol 
7-Ethoxycoumarin 
Phenacetin 
7.5 
1.2 
5.1 
(50,51) 
2A6 Coumarin 25 (52) 
2B6 17-α-ethynylestradiol 
Efavirenz 
48 
42 
(53) 
2C9 (S)-flurbiprofen 
(S)-Warfarin 
21 
4 
(54) 
2D6 Bufuralol 
3-Methoxyphenylethylamine 
4-Methoxyphenylethylamine 
39 
43 
42 
(55,56) 
2E1 N-Nitrosodimethylamine 5.6 and 59 (±b5) (57) 
2J2 Ebastine  2-17 (58) 
3A4 Testosterone 10-16 (59) 
4A11 Lauric acid 31 (60) 
 
17A1 
 
Progesterone 
17α-Hydroxyprogesterone 
Pregnenolone 
17α-Hydroxypregnenolone 
 
22, 41 
1.3, 10 
97, 61 
4,44 
 
(61,62) 
19A1 Androstenedione 
19-Hydroxy androstenedione 
19-Aldehyde androstenedione 
5 
34 
33 
(63) 
 
Table 2. Human P450: Coupling Efficiency (Product/NADPH Ratio) 
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ROS-dependent toxicity originating from P450-mediated uncoupling has been 
difficult to establish in vivo. Many in vitro reconstituted, microsomal, mitochondrial, and 
cellular studies have provided evidence that induction of P450s can cause elevated ROS 
production (59,64-70). However, in vivo studies in rodents indicate that toxicity may stem 
from depletion of reducing pools found in cells, such as GSH and reduced pyridine 
nucleotides (NADPH and NADH) (71,72). Conversely, other studies indicate that P450s 
may have protective effects in the case of the P450 1A subfamily (73,74). A major 
unanswered question in this field is how much do P450s contribute to ROS production? 
Although much has been written about both topics, there are major issues. One is that 
much of the experimental work has been done in cell culture, often with the use of 
inappropriate cellular models (e.g., that do not normally express P450s), or ROS has been 
measured using inadequate methods (e.g., several fluorescent dyes (75-77).)  A number 
of  papers have touted P450s as a major source of ROS (78-80) although others do not 
consider this to be as important as mitochondrial leakage, NADPH oxidase, and other 
sources (81). In vivo work with both rats and mice, using F2-isoprostane formation (82) 
(still accepted as the “gold standard” for measurement of oxidative stress (77)) showed 
that P450 induction elevated total tissue or urinary ROS only in the case of barbiturate 
induction, and that was at least in part due to an alteration in levels of pyridine nucleotides 
resulting from altered methyl transferase activity (71,72). However, other work done has 
shown that some localized changes (e.g., translocation of P450 2E1 to mitochondria and 
uncoupling there) may occur and be detrimental (64) (and these ROS changes were 
confirmed with isoprostane analysis). More in vivo studies will be needed to determine the 
contribution of P450s to proposed ROS-related toxicities (48).  
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Figure 5. Generalized Peroxidase Mechanism. L is either a histidine ligand or cysteine. 
From (83). 
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1.2.3. H2O2 as a P450 Co-substrate 
Reactions with H2O2 as the oxygen donor for P450 peroxygenase and peroxidase 
reactions are known (84,85). In these reactions, the ferric heme reacts directly with an 
oxygen of H2O2 or other hydroperoxide species and proceeds with heterolytic cleavage of 
the oxygen-oxygen bond to form Compound I (86). Other oxygen donating molecules 
(“oxygen surrogates”) have been noted to have oxidation activity including iodosylbenzene 
(87) and sodium chlorite (88). Additionally, Rittle and Green used m-chloroperbenzoic acid 
as an oxygen surrogate for CYP119 to successfully isolate Compound I (89). 
In the case of the peroxidase function of P450s, once Compound I is formed by 
either H2O2 or an organic hydroperoxide, a one-electron oxidation is performed on a 
substrate, resolving the porphyrin radical of Compound I to form Compound II (FeIV-OH) 
and a radical product. Compound II performs a subsequent one-electron reduction on 
another substrate generating ferric heme, water, and a second radical product (Fig. 5) 
(22). Mammalian P450s are known to act on endogenous hydroperoxide species, 
reducing them to their corresponding alcohols (90,91). This may be one of the metabolic 
mechanisms to reduce the levels of reactive hydroperoxides in cells.  
P450s can also perform peroxygenase reactions in which the enzyme can catalyze 
monooxygenase reactions without the requirement for ferric iron reduction or redox 
partner proteins. Peroxygenase reactions are thought to react in a chemically similar way 
to the monooxygenase activity. Various hydroperoxide substrates have been explored in 
the oxidation of P450 substrates (92-95). This reactivity provides further evidence that 
P450s may utilize endogenous hydroperoxides as co-substrates in vivo. However, there 
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are many technological challenges to study this hypothesis including the need for highly 
sensitive detection methods and the inherent instability of hydroperoxides (96). 
In mammalian P450s the reaction with H2O2 is generally very inefficient and is 
dependent on high concentrations of H2O2 that are well above estimated physiological 
concentrations, suggesting that this reaction does not occur in vivo (97). However, some 
bacterial enzymes are known to have fast catalytic rates and highly specific 
decarboxylation products of saturated fatty acids, e.g. P450SPα, P450BSβ (98), and OleT 
(99-101). These enzymes and other bacterial P450s are highly stable in the presence of 
H2O2. P450 BM3 (102A1) has been an important enzyme in the study of peroxygenases, 
especially after engineering an increase in stability (102-104). Other bacterial enzymes 
have also shown high stability in the presence of H2O2 (105,106). 
More recently, scientists have recognized the utility of peroxygenase reactions in 
the development of P450s as industrial biocatalysts (107,108). This industrial role has 
potential, and ongoing discovery and characterization of novel peroxygenase- and 
peroxidase-catalyzing P450s may lead to biocatalysts that produce useful products, e.g., 
biofuels and molecules that are difficult or expensive to synthesize. 
1.2.4. H2O2 as a P450 Inhibitor 
It has been known that H2O2 and other peroxides can inhibit P450 activity through 
heme degradation (109,110). Furthermore, this thesis focuses on the observation that 
incubation with H2O2 can also inhibit P450 by oxidizing the heme thiolate ligand to a 
sulfenic acid, thus inhibiting P450 catalysis (111,112). This phenomenon, first identified in 
human recombinant P450 4A11 (112), can affect other human P450 enzymes, as well as 
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other drug metabolizing enzymes. Spectral studies indicated that loss of the proximal 
heme ligand inhibited carbon monoxide binding and/or ferric heme iron reduction by 
NADPH-P450 reductase but can be reversed using a reducing agent, e.g., dithiothreitol 
(DTT), tris-(carboxyethyl)phosphine (TCEP), or sodium dithionite (Na2S2O4). In these 
studies, human P450s 2D6, 2C8, 3A4, and 4A11 exhibited redox sensitivity and P450 1A2 
was redox insensitive, suggesting that there is differential redox regulation among P450s 
(111). P450 1A2 was found to undergo extensive oxidation of one ancillary cysteine (Cys-
159) that had no effect on catalysis. This was contrary to the case of P450 3A4, which 
showed an irreversible inhibition related to hyperoxidation of ancillary Cys-468. This may 
be reasonable, as Sevrioukova has recently reported a cysteine-depleted P450 3A4 
enzyme with higher catalytic activity (113). 
P450s 2D6, 2C8, and 4A11 behaved similarly both in inhibitory and spectral 
aspects (112). In anaerobic spectral studies, P450s in the presence of CO, NADPH-P450 
reductase, and NADPH exhibited a maximal absorbance of 420 nm, indicating a 5-
coordinate heme center. After the addition of dithionite, the typical 450 nm absorbance 
was observed. This change was interpreted as H2O2-dependent oxidation of the heme-
thiolate ligand to a sulfenic acid which lost iron coordination. Dithionite was then able to 
reduce the sulfenic acid, allowing for re-liganding of the thiolate to the iron (Figure 6).  
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Figure 6. Sulfenylation of the Heme-Thiolate Ligand. The heme-thiolate cysteine is 
oxidized to a sulfenic acid. NADPH-P450 reductase cannot reduce the sulfenic acid, but 
can reduce the heme iron, allowing iron to bind CO and produce a 420 nm absorbance 
band. Adding dithionite reduces the sulfenic acid, allowing the thiolate to religand red 
shifting the absorbance band to 450 nm.  
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There have been multiple reports of variation in pharmacokinetics (PK) of drugs 
due to disease and/or inflammation (114). PK differences have been observed in celiac 
patients (which were reversed with treatment (115)) in which ROS levels are elevated, in 
untreated rheumatoid arthritis patients with extended verapamil half-lives compared to 
treated patients (116), and in P450 1A2 activity in patients with heart failure (117). Other 
reports highlighting a two- to five-fold change increase in the area under the curve (AUC) 
in P450 substrates has been reviewed in detail recently by Coutant and Hall (118,119). 
There is a strong link between autoimmune and inflammatory diseases to increased ROS 
production and also transcriptional downregulation of P450s (118-120). The redox 
sensitivity observed with some P450s may explain this variability, or at least contribute to 
it. Further testing in cellular and animal models is needed to confirm this, in that an 
alternate explanation is that the inflammation lowers overall levels of P450s at a pre-
translational level or through other phenomena (121,122).  
This inhibition may function as a sensor where P450s are switched off when there 
is a high oxidizing environment and a low amount of NADPH may be present. The reducing 
equivalents of NADPH and/or NADH may be required to perform functions critical for life 
such as reversing glutathionylated glyceraldehyde-phosphate dehydrogenase (GAPDH) 
(123) or maintaining general redox homeostasis (124-126). This may also be a negative 
feedback loop in place to limit uncoupling and further H2O2 production. Interestingly, in 
1971 Hrycay and O’Brien hypothesized that heme-thiolate sulfenylation could occur and 
that modified P450s would preferentially catalyze peroxidase reactions over 
monooxygenase reactions (110). This hypothesis requires further testing, however 
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switching the P450 oxygen donor to H2O2 and reducing the need for electrons from a redox 
partner could be beneficial in times of ROS stress.  
1.3. H2O2 in Signaling 
In recent years H2O2 has been recognized as an important secondary signaling 
molecule, and several laboratories have characterized redox sensitive enzymes 
(127,128). ROS have been shown to react specifically with several amino acids, but the 
sulfur-containing residues cysteine and methionine are the most susceptible to oxidation. 
The first step of cysteine oxidation by H2O2 is formation of a sulfenic acid (-SOH), initially 
characterized as an anthraquinone-sulfenic acid by Fries (129) and later by Bruice (130). 
This oxidation can occur at rates between 10-1 M-1 s-1 (GSH) and 108 M-1 s-1 (peroxiredoxin) 
(128) (Fig. 7). This large variation in reactivity is due at least in part to the pKa of the 
particular oxidized cysteine. Sulfenic acids are reactive species and readily react with free 
thiols to form disulfide bonds through a dehydration reaction or through a sulfenamide 
intermediate (131). This is thought to be the general mechanism of physiological disulfide 
bond formation (Fig. 7). The reaction can occur in an intra- or intermolecular fashion with 
free thiols (including GSH) and can be reversed by an NADPH-dependent reaction 
catalyzed by glutaredoxin (132). Sulfenic acids can be further oxidized to dioxidation 
(sulfinic acid, SO2-) and trioxidation products (sulfonic acid, SO3-), which are mostly 
irreversible and induce protein degradation and cellular stress responses (Fig. 1) (133). 
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Figure 7. General Redox Cycle of Protein Thiols. In the presence of H2O2, thiols can 
be oxidized to sulfenic acids, which may elicit a physiological response. Sulfenic acids 
can then form disulfide bonds, which can be reduced to free thiols. Sulfenic acids can 
also be further oxidized to sulfinic or sulfonic acids, which can trigger cellular damage 
responses. From (29)  
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 Oxidative regulation of cysteines in proteins have been known for quite some time. 
Evidence of oxidative inhibition of GAPDH (134) and papain (135) led to an interest in the 
field (136). After researchers determined conditions to promote the stability of sulfenic 
acids, they could be studied in a more systematic fashion (137-139). Recently, 
mechanisms of stability and function have been elucidated. In the case of epidermal 
growth factor receptor (EGFR), a sulfenic acid is formed in the kinase domain of the protein 
(Cys-797) in an H2O2-dependent fashion, causing autophosphorylation and activating the 
EGFR signaling cascade in an EGF-independent manner. This sulfenic acid is stabilized 
by a hydrogen bond with Arg-841, which, when mutated confers resistance to oxidative 
activation (140). Additionally, tyrosine phosphoprotein phosphatase 1B (PTP1B) (141), 
GAPDH (123), Kelch-like ECH-associated protein-1 (Keap1) (142,143), P450s (111,112), 
and many others (144) have been found to be regulated by sulfenic acid formation. 
Methods for detecting and analyzing cysteine oxidation have remained challenging, but 
recent advances in chemical trapping methods and in our understanding of redox biology 
provide promising new ways to elucidate redox functions of cysteines (145,146). 
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Figure 8. Drug Metabolism Enzyme Contribution. (A) Human oxidoreductases 
participating in the metabolism of drugs. (B) Human P450 enzymes in the metabolism of 
drugs. From (17) 
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1.4. P450 Posttranslational Regulation 
There is extensive knowledge on the transcriptional regulation of P450s, but 
knowledge of the posttranslational regulation of P450 enzymes is limited (147). P450 
transcriptional induction by xenobiotics such as barbiturates and polyaromatic 
hydrocarbons has been studied extensively because this upregulation potentially effects 
drug-drug interactions and pharmacokinetic profiles of administered drugs (148).  
The study of posttranslational regulation of P450 enzymes has not been fully 
evaluated.  Several studies have assessed P450 phosphorylation but is not a field that 
has garnered much attention. Of the phosphorylation sites identified, they have been 
characterized as inhibitory either directly or as phosphodegrons involved in the ER-
associated degradation (ERAD) pathway (149-151). 
1.5. Specific P450 Enzymes Studied in this Thesis 
1.5.1. Rationale 
The redox sensitivity of P450 enzymes was first observed by the laboratory of 
Jorge Capdevila and Donghak Kim performed initial investigations in the redox sensitivity 
of P450 4A11. P450 4A11 was chosen because this was the first enzyme where the 
response was seen. P450s 1A2, 2C8, 2D6, and 3A4 were selected for three reasons: (1) 
these enzymes have been expressed and purified in this laboratory with established 
protocols to monitor and assess modulations in enzymatic catalysis, (2) these four 
subfamilies of P450 are diverse in substrate recognition and major contributors to drug 
metabolism (Fig. 8), and (3) the data indicate that these enzymes have different responses 
to oxidation which is notable for discerning the mechanism of action.  
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1.5.2. P450 1A2 
P450 1A2 makes up a considerable amount of the total P450 in microsomes with 
approximately 10% of total P450 content (152). Known inducers include polyaromatic 
hydrocarbons (which are also substrates that can be bioactivated to carcinogens) and 
cruciferous vegetables. Some xenobiotic substrates for P450 1A2 are acetaminophen, 
phenacetin, caffeine, and theophylline among many others (153).  
1.5.3. P450 2C8 
This enzyme is not as well-known as a drug metabolizing enzyme but is closely 
related to 2C9 and 2C19 which are both major metabolizers of xenobiotics. P450 2C8 is 
involved in the metabolism of taxol and the production of epoxyeicosatrienoic acids (EETs) 
from arachidonic acid. P450 2C8 is mostly expressed in the liver and kidney but is also 
found in many other tissues. P450 2C8 was found to be a cause of the withdrawal of the 
HMG-CoA inhibitor cerivastatin due to a drug-drug interaction with gemfibrozil which 
caused rhabdomyolysis (154).  
1.5.4. P450 2D6 
P450 2D6 is a very important enzyme for drug metabolism. To date there are over 
160 variants (www.pharmvar.org) with varying abilities to catalyze metabolism of drugs. 
P450 2D6 is known to metabolize opioids, debrisoquine, and many others. During drug 
development, scientists try to design therapeutics that are not metabolized by P450 2D6 
due to this high variability.  
1.5.5. P450 3A4 
P450 3A4 is the most abundant human P450 in the liver and is the major 
metabolizer of xenobiotics. P450 3A4 is involved in the metabolism of more than 50% of 
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all small molecule drugs developed in the last ten years (18). This enzyme has a very 
large substrate binding pocket (>1300 Å3) that can facilitate many substrates (155). 
Because of this substrate promiscuity, there is large concern for possible drug-drug 
interactions that may cause toxicity. P450 3A4 is the main target of inhibition by molecular 
components in grapefruit juice, which leads to the recommendation for avoidance of the 
fruit when taking certain medications (156). 
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Figure 9. 20-HETE Contributes to Endothelial Dysfunction. 20-HETE increases 
NADPH-oxidase function and uncouples nitric oxide synthase contributing to endothelial 
dysfunction. Superoxide produced dismutates to H2O2 which inhibits P450 4A11, 
reducing 20-HETE production in a putative negative feedback fashion. Adapted From 
(157)  
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1.5.6. P450 4A11 
At least 13 human P450 enzymes (2C8, 2C9, 2J2, 2U1, 4A11, 4F22, 4F12, 4V2, 
4F2, 4F3, 4F8, 5A1, and 8A1) utilize fatty acids and/or eicosanoids as substrates (9). P450 
4A11 is primarily an ω-hydroxylase, with its main endogenous role apparently being the 
conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) (158). P450 
4A11 can also catalyze oxidations of other fatty acid substrates, including lauric acid (60):   
CH3(CH2)nCO2H —> HOCH2(CH2)nCO2H 
P450 4A11 is expressed mainly in the liver, kidney, and vasculature (159,160), 
and Subfamily 4A P450 enzymes have been associated with vascular dysfunction and 
hypertension in rodent models and humans (161). The P450 4A11 F434S variant has 
been associated with increased blood pressure in several populations studied (162-167). 
20-HETE plays opposing roles, having both pro- and anti-hypertensive actions by 
promoting vasoconstriction or natriuresis, respectively (168). 20-HETE has been reported 
to induce transcription of NADPH oxidase, activating this enzyme complex through protein 
kinase C (169-172), has been reported to increase mitochondrial reactive oxygen species 
(ROS) production (173), and is implicated in nitric oxide synthase uncoupling (157). It 
follows then, that the oxidative inhibition of P450 4A11 described in this thesis might act 
as a negative feedback loop to limit 20-HETE production (Fig. 9). Studies with P450 4A11 
transgenic mice have identified P450 4A11 regulation via fasting and growth hormone 
(174) and that 20-HETE and P450 4A11 activity may uncouple the renal renin angiotensin 
system (175).   
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1.6. Research Aims 
My dissertation research focuses on discerning the mechanism of redox 
dependent modulation of P450 activity. In this introduction I have tried to highlight the 
complex relationship between cytochrome P450 enzymes and H2O2. This redox 
relationship has been studied in some form or another for the last fifty years. Despite this 
effort, no one has reported the phenomenon of thiol redox-mediated activity modulation of 
P450s to my knowledge.  
One of the more important questions is how would oxidation of some P450 
enzymes confer a biological advantage through heme-thiolate sulfenylation? There are 
currently several hypotheses postulated:  
(1) Limitation of futile cycling. Without substrate present P450 enzymes are still 
able to be reduced allowing the ferrous heme to bind oxygen. The activated oxygen will 
likely be released as superoxide if no substrate is present. The heme-thiolate ligand 
provides sufficient electronegativity to allow for this binding. It follows then, that the lack 
of this fifth ligand would prevent oxygen binding. This could be beneficial for the cell 
because it limits oxygen and NADPH consumption while reducing the amount of harmful 
ROS produced.  
(2) Inactivation during an oxidative insult. In times of oxidative stress, cells require 
reducing equivalents in the forms of GSH and NAD(P)H to counteract and survive the 
stress. P450s that are mainly xenobiotic metabolizing enzymes (e.g. P450s 3A4 and 2D6) 
are not necessary for survival and can therefore be inactivated until the redox environment 
reaches homeostasis. This would allow NADPH to be diverted to enzymes devoted to 
combating oxidative stress, e.g. glutathione reductase and thioredoxin reductase.  
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(3) Oxidative modification as a degradation signal. Oxidation of cysteine thiols has 
been shown to signal proteins for degradation. This is likely a protective mechanism as 
oxidation can modify other amino acids, inactivating proteins. Since cysteines are the most 
easily oxidized amino acids in proteins, this process serves as a chemosensor for 
damage. Downregulation of P450s due as response to inflammation has been reported 
(118). Oxidation of thiols of P450s may be an acute response to inflammatory insults. With 
the goal of removing (in)active P450 enzyme before P450 genes are transcriptionally 
downregulated.  
(4) Another reason for this modification would be the one originally proposed by 
Hrycay and O’Brien (110). They postulated that formation of a sulfenic acid on the heme-
thiolate ligand would alter the spin state of the heme, allowing the enzyme to more easily 
catalyze peroxidatic reaction with H2O2 being a co-substrate, donating oxygen. This could 
be possible because P450 enzymes can utilize oxygen from peroxides and peracids as 
co-substrates. During oxidative stress events, highly reactive lipid peroxides and 
isoprostanes are produced. This P450 sulfenylation may allow for more facile metabolism 
of these damaging oxidative byproducts.  
When I commenced work on this project, the original scope was centered around 
P450 4A11. This study involved specifically looking at redox sensitivity of the enzyme and 
then elucidating differences between single nucleotide variants of P450 4A11 with respect 
to blood pressure regulation.  After the observation that other P450s are regulated in a 
similar fashion, the decision was made to pursue the mechanism behind this further.  
My aims became centered around the hypothesis that P450 enzymes are (1) redox 
regulated and (2) this regulation is protective for the organism. To test the first part of this 
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hypothesis, I developed chemoproteomic and spectroscopic methods that were coupled 
with activity assays specific for each P450 tested. Selectively labeling sulfenic acids 
followed by LC-MS/MS quantitative analysis and verifying cysteine-heme ligandability 
spectroscopically proved to be a powerful technique that is outlined in Chapter II.  
These techniques were first applied to P450 4A11. As this was the first enzyme 
discovered to have redox sensitivity, the resulting IC50 of ~140 μM for H2O2 preincubation 
was the lowest observed to date. This loss of activity correlated with heme-thiolate sulfenic 
acid formation in a H2O2 concentration-dependent manner. I was able to verify this 
correlation with spectroscopic techniques. Heme-thiolate sulfenylation of P450 4A11 was 
also observed in mouse liver and kidney microsomes via LC-MS/MS analysis. This work 
is further outlined in Chapter III.  
The proteomic data obtained from the mouse liver and kidney microsomes 
mentioned above was acquired using a data-dependent analysis (DDA) “shotgun” 
approach and, interestingly, many other mouse P450s as well as other drug metabolizing 
enzymes showed evidence of heme-thiolate sulfenylation. Based on this data, I 
hypothesized that other human P450s are also redox sensitive. I repeated the microsome 
labeling experiment with human liver and kidney microsomes which showed evidence of 
sulfenylation of P450s and other enzymes. I tested other P450s for heme-thiolate 
sulfenylation as described previously and was able to classify P450s tested into three 
redox classes: (1) heme-thiolate sensitive (2) insensitive and (3) ancillary cysteine 
sensitive. This work is described in Chapter IV.  
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Chapter II 
2. Techniques and Methods 
2.1. Introduction 
The analytical techniques developed during my thesis work allowed me to answer 
the questions posed and test proposed hypotheses efficiently. With that in mind, the 
optimized techniques utilized in Chapters III and IV are included here for reference. For 
methods that were challenging to develop and novel, a brief rationale is included to explain 
the reason 
2.2. Chemical Synthesis 
2.2.1. Rationale 
Both the isotope-coded dimedone iododimedone labeling and iodoacetanilide 
alkylation methodologies and synthesis have previously been reported (176,177). 
Isotopically labeled iodoacetanilide was selected because of the ease of synthesis and 
the mass difference of 5 Da between the two molecules provided sufficient m/z separation 
between multiply charged peptide species (M + 2H, M + 3H, M+ 4H). 
2.2.2. Iododimedone 
Iododimedone was prepared from dimedone (4 mmol scale) by iodination with N-
iodosuccinimide (178): Yield 48%, mp 145-146 °C; high resolution mass spectrometry 
(HRMS) for C8H12O2I m/z 266.9882 (MH+), found 266.9881 (Δ 0.4 ppm); 1H-NMR (400 
MHz, CDCl3) δ 1.04 (s, 6H, (CH3)2), 2.50 (d (splitting due to I), 4H, CH2), 6.35 (s, 1H, CHI) 
(literature mp 155 °C (179)). 
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2.2.3. d6-Dimedone 
A modification of the basic procedure of Yeo and Carroll (177) was used. Diethyl 
malonate and mesityl-d10-oxide were condensed in an ethanolic solution of NaOC2H5 
under reflux, followed by decarboxylation with NaOH under reflux. After neutralization the 
filtrate was collected and extracted into ethyl acetate. The product was concentrated by 
partial removal of solvent in vacuo and trituration with hexanes to yield crystalline d6-
dimedone in 85% yield: mp 147-148 °C; HRMS for C8H7D6O2 m/z 147.1292 (MH+), obs 
147.1284 (Δ 5.4 ppm); 1H-NMR (400 MHz, CDCl3) δ 2.52 (s, 5H, -CH2-), 3.33 (s, 2H, CO-
CH2-CO) (180) (lit mp 145-147 °C (180)). 
2.2.4. d0-Iodoacetanilide 
Iodoacetanilide was prepared from iodoacetic acid (2.53 mmol, 470 mg) and 
aniline (2.53 mmol, 235 mg) by amide coupling with dicyclohexylcarbodiimide (2.53 mmol, 
522 mg) (176): yield 70%, 1H-NMR (600 MHz, acetone-d6) δ 9.51 (bs, 1H, NH) 7.64 (d, 
2H, o-Ar), 7.31 (t, 2H, m-Ar), 7.02 (t, 1H, p-Ar), 3.90 (s, 2H, CH2I), 13C-NMR (150 MHz, 
acetone-d6) 167.0, 140.1, 129.7, 124.6, 120.0, 0.72.   
2.2.5. d5-Iodoacetanilide 
d5-Iodoacetanilide was prepared from iodoacetic acid (2.53 mmol, 470 mg) and d5-
aniline (2.53 mmol, 248 mg) by amide coupling with dicyclohexylcarbodiimide (2.53 mmol, 
522 mg) (176): yield 89%, 1H-NMR (600 MHz, acetone-d6) δ 9.53 (bs, 1H, NH), 3.90 (s, 
2H, CH2I), 13C-NMR (150 MHz, acetone-d6) 167.0, 139.8, 129.1, 124.1, 119.6, 0.75.   
2.3. Expression and Purification of Human Cytochrome P450 Enzymes 
Human P450 4A11 (wild-type and F434S, C52S, C85S, C199S, C255S, and 
C512S mutants) was expressed and purified as described previously by Donghak Kim 
35 
 
(60,181). Escherichia coli recombinant rat NADPH-P450 reductase and human liver 
cytochrome b5 (b5) were prepared as described by Hanna et al. (182) and Guengerich 
(183), respectively. 
Human P450s 1A2 (184), 2C8 (185),  2D6 (186), and 3A4 (187) (all with C-terminal 
(His)6 tags) were expressed and purified. E. coli recombinant rat NADPH-P450 reductase 
and human liver b5 were prepared as described by Hanna et al. (182) and Guengerich 
(183), respectively. 
2.4. Cloning of P450 4A11 
Site-Directed Mutagenesis—P450 4A11 was subcloned into a pBlueScript vector 
to preform site-directed mutagenesis. Residues from each site were converted to serine 
by using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). The 
resulting plasmids were sequenced to confirm successful mutation and subcloned into a 
pCW expression vector. 
2.5. Tissue Samples 
2.5.1. Mouse Tissue 
All experiments using mice were conducted with approved protocols by the 
Institutional Animal Care and Use Committee of Vanderbilt University and in accordance 
with the NIH Guide for the Care and Use of Laboratory animals. 129/Sv mice carrying one 
copy of the human  P450 4A11 gene (CYP4A11) (under control of its native promoter were 
generated as previously described (175)) were provided normal chow diet (Purina 
Laboratory Rodent 5001; St. Louis, MO) with free access to water and were housed in 
an Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC)-accredited, temperature-controlled facility with a 12 h light–dark cycle. All 
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studies were conducted in mice aged 6-28 weeks of age. CYP4A11 transgenic mice 
were crossed with pure Sv129 wild type mice and offspring were genotyped for the 
presence of a single copy of the human CYP411 gene as previously described (175). 
Organs were collected from male transgenic mice immediately after sacrifice and used 
for microsomal preparations as described below. 
2.5.2. Human Tissue 
Tissues were collected and stored by the Vanderbilt University Medical Center 
Tissue Repository using Cooperative Human Tissue Network (CHTN) approved standard 
operating procedures, under a waiver of consent and anonymized. After collection, areas 
of necrosis or cauterized areas were removed and then sectioned into normal and tumor 
tissue. A representative section of each tissue type and/or disease type was fixed in 
formalin and processed, and a hematoxylin and eosin stained section was obtained and 
reviewed by a board-certified pathologist to ensure sample integrity and usefulness in 
research. Kidney and liver samples (five each, collected within one year of analysis, 
decoded) used for this study were snap-frozen in liquid nitrogen and stored at -80 °C. 
2.6. Kinetic Assays 
2.6.1. P450 4A11 
Assays were done as described previously (60) with minor changes. Typical 
incubations included 0.2 μM P450 4A11, 0.4 μM NADPH-P450 reductase, 0.4 μM b5, 150 
μM L-α-dilauroyl-sn-glycero-3-phosphocholine (DLPC, Sigma Aldrich), 100 mM potassium 
phosphate buffer (pH 7.4), and the indicated concentration of lauric acid ([1-14C]-lauric 
acid, usually added as an aqueous 10 mM stock solution of sodium laurate) in a final 
volume of 0.25 ml. b5 was included because it stimulates the catalytic activity (60). 
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Following temperature equilibration to 37 °C for 5 min, reactions were initiated by the 
addition of an NADPH-regenerating system consisting of 0.5 mM NADP+, 10 mM glucose 
6-phosphate, and 1 IU ml–1 yeast glucose 6-phosphate dehydrogenase (188). Reactions 
generally proceeded at 37 °C for 2 min and were terminated with 1.0 ml of ethyl acetate 
containing 0.1% CH3CO2H (v/v) and, following mixing with a vortex device, the mixtures 
were centrifuged (103  g for 10 min). A 0.8 ml aliquot of the ethyl acetate layer (upper 
phase) was transferred to a clean tube, and the solvent was removed under an N2 stream. 
The dried extracts were dissolved in 200 μl of 1:1 mixture of H2O:CH3CN containing 
0.1% CH3CO2H (v/v) and 10 μM butylated hydroxytoluene, and aliquots were analyzed on 
a reversed-phase (octadecylsilane, C18) HPLC column (5 μm, 2.1 mm × 100 mm (Waters, 
Milford, MA)) coupled with a radioactivity detector (IN/US Systems β-RAM, Tampa, FL). 
Reaction products and substrate were eluted at a flow rate of 0.6 ml min–1 using an 
increasing linear gradient of CH3CN (including 0.1% (v/v) HCO2H) from 35 to 95% (v/v) 
over 30 min.  
2.6.2. Other P450s 
Assays with P450s other than P450 4A11 were performed as described previously, 
with the modification of either preincubation with DTT (1 mM) for 10 min or not (the DTT 
remained in the reactions): P450 2C8–paclitaxel as substrate (189), P450 2C9—
tolbutamide as substrate (190), P450 2D6—bufuralol as substrate (186), P450 3A4—
nifedipine as substrate (191), P450 19A1—testosterone as substrate (63), P450 21A2—
progesterone as substrate (192), P450 2A6—coumarin as substrate (52), and P450s 1B1, 
1A1, and 1A2–7-ethoxyresorufin as substrate (193). 
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Assays with P450s were performed as described previously with P450 2C8–
paclitaxel as substrate (185,189), P450 2D6—dextromethorphan as substrate (186,194), 
P450 3A4—testosterone as substrate (191), and P450 1A2—phenacetin as substrate 
(193). b5 was only used in the P450 3A4 incubations. 
2.7. Protein Oxidation 
2.7.1. Rationale 
Optimizing conditions for sufficient oxidation was determined empirically. 
Considering that P450s require oxygen for catalysis, oxidation of the protein by H2O2 could 
not be done in a completely anaerobic environment which is ideal when determining 
concentration-dependent effects of oxidation. To overcome this, protein was oxidized 
initially in an anaerobic environment and, instead of removing H2O2 via buffer exchange, 
catalase was added in excess to remove H2O2. For activity assays, P450 was diluted in 
buffer that was not anaerobic to ensure sufficient oxygenation for the catalytic reaction.  
Dilution of the P450 to 500 nM during oxidation was required to obtain a 
reproducible inhibition. 
2.7.2. Method 
Purified recombinant P450  (0.4 ml of a 10 µM stock solution, stored at -80 °C in 
50 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol, 1 mM DTT, and 0.1 
mM EDTA) was thawed on ice and reduced for 30 minutes by the addition of 1 mM TCEP 
at 4 °C. A Zeba Spin Desalting Column (Thermo) pre-equilibrated with “oxidation buffer” 
(100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA and sparged with 
Ar) was used to remove reducing agents. Reduced protein was then diluted to a 
concentration of 500 nM using oxidation buffer. Aliquots were treated with varying 
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amounts of H2O2 or TCEP. Aliquots for the activity assay (175 pmol, described above) 
were incubated with H2O2 or TCEP for 15 minutes at 37 °C. Human erythrocyte catalase 
(10 units, Sigma, catalog #C3556) was added and incubations proceeded at 23 °C for 5 
minutes to remove H2O2. These samples were used to measure catalytic activity as 
described above. 
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Figure 10. Scheme for Analysis of Sulfenic Acids and Disulfides of P450 Enzymes.  
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2.8. Chemical Proteomic Labeling Techniques 
2.8.1. Rationale 
Chemical proteomic labeling can be visualized in Figure 10. These chemical 
labeling techniques required multiple iterations of optimization to prove effective. For 
isotope-coded dimedone/iododimedone (ICDID) labeling, the rate of alkylation for 
dimedone with sulfenic acid is ~20 M-1 s-1, which is very slow. A 10,000-fold molar excess 
of dimedone co-incubated with oxidant (H2O2) for 2 hours with the target protein is required 
to achieve sufficient labeling as determined empirically. Labeling may also be slowed due 
to solvent accessibility of the target cysteine. Newer reagents have been synthesized 
recently that are more efficient at alkylating sulfenic acids (195). ICDID labeling was 
selected because it was the most straightforward method to measure relative sulfenylation 
of cysteines over a variety of peroxide concentrations.  
Isotope-coded affinity tag (ICAT) labeling with iodoacetanilide for disulfide bond 
determination also proved to be challenging. If left at a neutral pH, disulfide bonds tend to 
rearrange readily and quickly (196). There are two strategies to avoid this: (1) acidification 
to protonate all free thiols and denature and precipitate protein or (2) rapid alkylation. A 
hybrid approach was used to take advantage of both strategies. Acidification with 
trichloroacetic acid (TCA) allowed for the rapid quenching of thiols and subsequent 
precipitation of proteins. Resuspension of the protein precipitate in pH 8 buffer with SDS 
and “heavy” alkylating agent exposes all free thiols for fast alkylation. Reprecipitation of 
the protein removes the “heavy” reagent. Subsequent resuspension in reducing agent and 
the “light” alkylating agent alkylates the remaining thiols presumably in disulfide bonds. 
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Precipitating protein twice reduced alkylated protein yields, however, using recombinant 
protein ensures sufficient amounts of starting protein.  
After chemoproteomic labeling was complete (either ICDID or ICAT) samples were 
loaded on onto an SDS-PAGE gel to remove reagents. This process allowed for 
separation of aggregated and multimeric protein by band excision of the monomeric 
protein band. Coomassie Brilliant Blue R staining of the gel provided an estimate of protein 
recovery in relation to a loading control lane. 
2.8.2. ICDID Labeling for Sulfenic Acid Identification 
Additional aliquots of oxidized protein (100 pmol) were incubated with 5 mM d6-
dimedone (from a 50 mM stock suspended in 100 mM sodium 3-[4-(2-hydroxyethyl)-1-
piperazinyl]propanesulfonate (HEPPS) buffer (pH 8.0) containing 5% NaCl (w/v)) for 2 
hours at 37 °C. Trichloroacetic acid was then added to a final concentration of 10% (w/v) 
and the samples were incubated on ice for 15 minutes. The enzymes in the samples were 
pelleted by centrifugation (12,000  g, 15 min, 4 °C). The supernatant was removed from 
each sample, and the pellet was washed with ice cold CH3CN. The pellet was 
resuspended in 20 µl of 100 mM HEPPS buffer (pH 8.0) containing 2% (w/v) SDS and 1 
mM TCEP, and reduction proceeded for 30 minutes at 37 °C. (d0)-Iododimedone (100 mM, 
in DMSO) was added to a final concentration of 10 mM, and incubation was done at 23 
°C in the dark for 30 minutes. Samples were subjected to SDS-polyacrylamide gel 
electrophoresis (10% Bis-Tris, NuPAGE, Invitrogen) separation and stained with 
SimplyBlue SafeStain (Invitrogen). The Mr region corresponding to each P450 was 
excised, digested with trypsin (8 ng/µl) for 16 hours in 25 mM NH4HCO3 buffer (pH 7.8) at 
37 °C, and subjected to LC-MS/MS analysis. 
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2.8.3. ICAT Labeling for Disulfide Bond Identification 
Additional aliquots of reduced, buffer exchanged protein (from above, 100 pmol) 
were incubated with H2O2 or TCEP for 15 minutes. Human erythrocyte catalase (10 units) 
was added and incubations proceeded at 23 °C for 5 minutes to remove H2O2. 
Trichloroacetic acid was then added to a final concentration of 10% (v/v) and the samples 
were incubated on ice for 15 minutes. The enzymes in the samples were pelleted by 
centrifugation (12,000   g, 15 min, 4 °C). The supernatant was removed from each 
sample, and the pellet was washed with ice cold CH3CN. The pellet was resuspended in 
50 µl of 100 mM HEPPS buffer (pH 8.0) containing 2% (w/v) SDS and 10 mM d5-
iodoacetanilide, and alkylation proceeded for 30 minutes at 23 °C, shaking in the dark. 
Protein was precipitated again using the same method as above to remove heavy reagent. 
The pellet was resuspended in 20 µl of 100 mM HEPPS buffer (pH 8.0) containing 2% 
(w/v) SDS and 1 mM TCEP, and reduction proceeded for 30 minutes at 50 °C. d0-
Iodoacetanilide (100 mM, in acetone) was added to a final concentration of 10 mM, and 
incubation was done at 23 °C in the dark for 30 minutes, shaking. Samples were subjected 
to SDS-PAGE (10% Bis-Tris, NuPAGE, Invitrogen) separation and stained with 
SimplyBlue SafeStain (Invitrogen). The Mr region corresponding to P450 4A11 was 
excised, digested with trypsin (8 ng/µl) for 16 hours in 25 mM NH4HCO3 buffer (pH 7.8) at 
37 °C and subjected to LC-MS/MS analysis. 
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2.9. Preparation of Microsomes 
2.9.1. Rationale 
When analyzing specific proteins in a complex mixture, an enrichment strategy is 
optimal. To enrich for ER proteins, microsomes were prepared by differential 
centrifugation followed by SDS-PAGE separation. Since P450s are all approximately 50 
kDa in molecular weight, excising the “P450 region” from the gel provided sufficient 
enrichment to quantify dimedone-labeled (sulfenylated) peptides. Mouse microsomes 
were digested with chymotrypsin to produce peptides unique to the heme-thiolate 
containing peptide sequence in 4a/4A enzymes (Fig. 11). 
2.9.2. Microsomal Preparation 
Microsomes from human and mouse tissues were prepared with slight 
modifications of published methods (188). For ICDID labeling studies, Buffer A (0.10 M 
Tris-acetate buffer (pH 7.4) containing 0.10 M KCl, 1.0 mM EDTA, and 20 µM butylated 
hydroxytoluene) was sparged with Ar before use. Tissue samples were homogenized in 
buffer A using a Teflon®-glass Potter-Elvehjem device and centrifuged at 104  g for 20 
min. at 4 °C. Post-mitochondrial supernatants were then treated as described (188), and 
the final microsomal pellets were resuspended in 100 mM HEPPS buffer (pH 8.0) 
containing 1.0 mM EDTA. Aliquots of these samples were incubated with 10 mM d6-
dimedone for 1 hour at 37 °C. Aliquots were reduced with 1.0 mM TCEP at 37 °C for 30 
minutes and then 10 mM (d0)-iododimedone was added. The protein concentrations of 
microsomes were estimated using a bicinchoninic acid (BCA) assay (Pierce). Alkylated 
microsomes (60 µg protein) were subjected to SDS-polyacrylamide gel electrophoresis 
(10% acrylamide gel, vide supra), and the P450 region (Mr 40-60 kDa) was excised, 
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digested with trypsin (8 ng/µl) for 16 hours in 25 mM NH4HCO3 buffer (pH 8.0) at 37 °C, 
and subjected to LC/MS/MS analysis as described below. 
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Figure 11. Cleavage Sites of P450 Subfamily 4A Enzymes. Closed upward arrows 
denote tryptic cleavage sites and open downward arrows denote chymotryptic cleavage 
sites. 
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2.10. LC-MS/MS Peptide Identification 
Extracted peptides from mouse microsomes or recombinant P450s were analyzed 
on a nanoLC Ultra system (Eksigent Technologies, Dublin, CA) interfaced with an LTQ 
Orbitrap XL mass spectrometer (Thermo Scientific, San Jose, CA). Approximately 2.5 µg 
(microsomes) or 10 pmol (recombinant P450) of peptides was reconstituted in 0.1% 
HCO2H (v/v) and pressure-loaded (1.5 µl min-1) onto a 360 µm outer diameter × 100 µm 
inner diameter microcapillary analytical column packed with Jupiter octadecylsilane (C18) 
(3 µm, 300 Å, Phenomenex) and equipped with an integrated electrospray emitter tip. 
Peptides were then separated with a linear gradient formed with 0.1% HCO2H in H2O 
(solvent A) and 0.1% HCO2H in CH3CN (solvent B) (all v/v) by increasing from 2-45% B 
(v/v) over a period of 0-45 minutes at a flow rate of 500 nl min-1. The spray voltage was 
set to 2.3 kV and the heated capillary temperature to 200 °C. Higher energy collisional 
dissociation (HCD) and collision-induced dissociation (CID) MS/MS spectra were 
recorded in the data-dependent mode using a Top 2 method for each fragmentation mode. 
MS1 spectra were measured with a resolution of 70,000, an automatic gain control (AGC) 
target of 1e6, and a mass range from m/z 300 to 1,500. HCD MS/MS spectra were 
acquired with a resolution of 7,500, an AGC target of 1e5, and a normalized collision 
energy of 35. CID MS/MS spectra were acquired with normalized collision energy of 35 
with a 50 ms max injection time.  Peptide m/z values that triggered MS/MS scans were 
dynamically excluded from further MS/MS scans for 20 s, with a repeat count of 1.  
For samples produced with human microsomes, an analytical column was packed 
with 20 cm of C18 reverse phase material (Jupiter, 3 μm beads, 300 Å, Phenomenex) 
directly into a laser-pulled emitter tip.  Peptides (500 ng) were loaded on the capillary 
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reverse phase analytical column (360 μm O.D.  100 μm I.D.) using a Dionex Ultimate 
3000 nanoLC and autosampler.  The mobile phase solvents consisted of 0.1% HCO2H, 
99.9% H2O (solvent A) and 0.1% HCO2H, 99.9% CH3CN (solvent B).  Peptides were 
eluted at a flow rate of 400 nl/min.  The 90-minute gradient consisted of the following: 1-
3min, 2% B (sample loading from autosampler); 3-70 min, 2-40% B; 70-78 min, 40-95% 
B; 78-79 min, 95% B; 79-80 min, 95-2% B; 80-90 min (column re-equilibration), 2% B (all 
v/v).  A Q-Exactive mass spectrometer (Thermo Scientific), equipped with a 
nanoelectrospray ionization source, was used to mass analyze the eluting peptides.  The 
instrument method consisted of MS1 using an MS AGC target value of 1e6, followed by 
up to 20 MS/MS scans of the most abundant ions detected in the preceding MS scan.  A 
maximum MS/MS ion time of 100 ms was used with a MS2 AGC target of 1e5 and an 
intensity threshold of 5e4.  Dynamic exclusion was set to 15 seconds, HCD collision 
energy was set to 27 normalized collision energy (NCE), and peptide match and isotope 
exclusion were enabled. 
2.11. Proteomic Data Analysis 
2.11.1. Rationale 
MS1 precursor quantitation was selected because this is a robust method for 
quantitation of peptides, especially when using a recombinant protein when the sample 
is not complex. This method was extended to quantitation of peptides in human liver and 
kidney microsomes. This was done for two reasons, (1) precursor quantitation of 
heavy/light-paired peptides allows for a seemingly unlimited amount of peptides to be 
quantified in a single run in a similar fashion to stable isotope labeling of amino acids in 
cell culture (SILAC) quantitation and (2) MS2 quantitation would require multiple runs per 
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sample including pilot runs to determine peptide elution time and positive peptide 
identification to schedule either MRM, PRM, or DIA methods.   
2.11.2. Method 
Raw data files were analyzed using MyriMatch software (Version 2.2.140) (197), 
and in the case of the mouse microsomes, also MS-GF+ (v2016.12.12) (198), against a 
decoy protein database consisting of a forward and reversed human Uniprot/Swissprot 
database with only reviewed proteins included (Version 20170202–20,165 entries).  For 
mouse microsomes, a mouse Uniprot/Swissprot database with only reviewed proteins 
included was used (Version 20150825–16,718 entries). Trypsin (human microsomes and 
recombinant P450) or chymotrypsin (mouse microsomes) with fully specific digestion was 
used as the enzyme search parameter. Chymotrypsin was used with the mouse samples 
in order discern between mouse P450 4a12 and 4a14 (Fig. 11). The number of missed 
cleavages permitted was two. Precursor ion mass tolerance was set at 10 ppm, and the 
fragmentation tolerance was 20 ppm for the database search. Methionine oxidation 
(15.9949 Da, dynamic) and cysteine modifications by d6-and d0-dimedone (i.e., derived 
from iododimedone) (144.1057 and 138.0681 Da, respectively, dynamic) were included 
as variable search modifications. For the mouse microsomes and recombinant P450 
assays, an additional low-resolution search was performed with the same databases 
where precursor ion mass tolerance was set at 10 ppm, and fragmentation tolerance set 
at 0.5 m/z. The maximum Q values of peptide spectrum matches were adjusted to achieve 
a peptide false discovery rate ≤5%, using IDPicker software (Version 3.1.642.0) (199). A 
spectral library of peptides was then created with IDPicker and loaded into Skyline 
Software for confident identification and quantitation of precursors pertaining to cysteine-
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containing peptides. MS1 precursor quantitation was performed as described previously 
(200,201).  The retention time of the identified peptide was used to position a retention 
time window (± 2.0 min) across the run lacking the same peptide identification. Second, 
the resolution for extracting the MS1 filtering chromatogram of the target precursor ions 
with both light and heavy labeled peptides was set to 60,000 at 400 Th. Then extracted 
ion chromatograms for the top three isotopic peaks were manually inspected for proper 
peak picking of MS1 filtered peptides and those with isotopic dot product scores lower 
than 0.8 were rejected. Additional criteria were used to further ensure the high accuracy 
and precision of quantification: S/N> 3.0 and baseline separation was required between 
the isotopic peaks of a quantifiable peptide and unknown isobaric interference. The ratios 
of peptide areas of light peptides to their heavy isotopes (RL:H) were calculated 
automatically. Quantification results were obtained from five biological replicates for 
human microsomes, four biological replicates for mouse microsomes, and two biological 
replicates for recombinant protein. 
2.12. Spectroscopic Techniques 
2.12.1. Rationale 
This method was chosen to take advantage of the inherent properties of P450 
enzymes which show strong absorbance at 450 nm when the heme iron is reduced to its 
ferrous form and bound to CO. A P450 concentration of 1 µM was used instead of 500 nM 
for this experiment to increase spectroscopic signal. Deaeration in conjunction with the 
use of protocatechuate dioxygenase greatly reduces the amount of molecular oxygen in 
the sample to decrease futile cycling of the reductase enzyme.   
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2.12.2. Method 
P450s were oxidized with H2O2 as above but the procedure was adapted slightly 
for spectroscopic assays. The enzyme was diluted with oxidation buffer to 1.0 µM prior to 
introduction of 1.0 mM TCEP or 500 µM H2O2. After oxidation, 30 units of catalase was 
added, and each sample was incubated at 23 °C for five minutes. To this solution, final 
concentrations of 1.0 µM NADPH-P450 reductase, 150 µM DLPC, and 0.1 unit/ml 
protocatechuate dioxygenase (Sigma) were added to an anaerobic cuvette, with NADPH 
(300 nmol, in aqueous solution) in a sidearm of the cuvette. Samples were degassed, 20 
µM 3,4-dihydroxybenzoate (Sigma, substrate for protocatechuate dioxygenase) was 
added to remove oxygen (202), and samples were further degassed using a manifold 
attached to both vacuum and purified Ar (203,204), and placed under an anaerobic CO 
atmosphere. The valves of the cuvettes were sealed, and multiple UV-visible absorbance 
spectra were recorded using an OLIS/Hewlett Packard 8452 diode array 
spectrophotometer (On-Line Instrument Systems, Bogart, GA). Spectra were collected 
from 380 to 600 nm before and after the addition of NADPH and then sodium dithionite 
(112). 
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Chapter III 
3. Heme-Thiolate Sulfenylation of Human Cytochrome P450 4A11 as a Redox Switch 
for Catalytic Inhibition 
3.1. Introduction 
As discussed in Chapter I, P450 4A11 was the first P450 enzyme shown to exhibit 
redox sensitivity. In this chapter, the steps to identify and verify this sensitivity are 
described using methods developed which are included in Chapter II.  
Since the main enzymatic product catalyzed by P450 4A11, 20-
hydroxyeicosatetraenoic acid) 20-HETE, is a molecule with opposing physiological 
activities depending on its site of production related to blood pressure regulation, this 
enzyme is of interest as a potential drug target for anti-hypertensive research.  
In this chapter, I used a combination of chemoproteomic and spectroscopic 
techniques to investigate the mechanism behind the redox sensitivity observed in P450 
4A11. The aims for this chapter were to prove the hypothesis that 4A11 is redox regulated 
through sulfenylation of the heme-thiolate ligand.  
3.2. Results 
3.2.1. Stimulation of P450 4A11 ω-Hydroxylation Activity by Reducing Agents 
In previous work the rates of ω-hydroxylation of lauric acid varied considerably, 
from 9-21 min-1, under varying conditions (60). When P450 4A11 was pretreated with 
either DTT or TCEP reagents in the preliminary experiments performed by Donghak Kim 
(Fig. 12), ω-hydroxylation activity was routinely increased two- to four-fold. Similar results 
were found with reduced GSH (results not presented). The ratio of the two major products, 
11- and 12-hydroxy lauric acid, remained constant with this activation, performed by 
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Donghak Kim (Fig. 13). These results indicated that P450 4A11 has a thiol-dependent 
redox sensitivity, which was investigated further. Redox-dependent activation was also 
reflected in the increase in kcat values for both the wild-type and F434S (rs1126742) (162) 
variants of P450 4A11 (2.1-fold) (Figs. 14A, 14B). The Km values with and without DTT 
remained constant between the wild type enzyme (63 ± 10 μM and 62 ± 15 μM, 
respectively) and the F434S variant (67 ± 7 μM and 58 ± 10 μM, respectively) (Figs. 14A, 
14B). Collectively, these results indicate that both wild-type and F434S variant P450 4A11 
are activated in a reducing environment, which may have biological relevance in vivo.  
Ten other human P450 enzymes were tested for thiol-dependent activation with 
their relevant substrates (Table 3). The highest stimulation observed among these was 
P450 2C9, with only a 33% increase. The reductive activation of P450 4A11 was unique 
among human P450 enzymes examined here. These analyses were performed by Leslie 
Nagy and Fred P. Guengerich. 
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Figure 12. Stimulation of Lauric Acid ω-Hydroxylation Activity by DTT and TCEP. 
P450 4A11 was pre-incubated with varying concentrations of either (A) DTT or (B) TCEP 
and rates of lauric acid ω-hydroxylation were measured.   
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Figure 13. ω/ω-1 Ratios with Stimulation of Lauric Acid ω-Hydroxylation Activity by 
DTT. P450 4A11 was pre-incubated with varying concentrations of DTT and rates of lauric 
acid ω- and ω-1 hydroxylation were measured.   
 
  
- D
TT
 M
+ 
D
TT
 2
0 
M
+ 
D
TT
 5
0 
M
+ 
D
TT
 1
00
 
M
+ 
D
TT
 5
00
 
M
+ 
D
TT
 1
00
0 
0
10
20
30
40
-1

n
m
o
l 
p
ro
d
u
c
t/
m
in
/n
m
o
l 
P
4
5
0
56 
 
 
 
Table 3. Effects of DTT on Catalytic Activities of P450 4A11 and Other Human P450s 
 
  
   Catalytic activity,  
nmol product/min/nmol P450 
 
Human 
P450 
Substrate Reaction -DTT +DTT (1 mM) % increase 
4A11 Lauric acid 12-OH 9.0 ± 1.1 38 ± 1 + 420 
2C8 Paclitaxel 6-OH 1.8 ± 0.1 1.9 ± 0.1 + 7 
2C9 Tolbutamide 1´-OH 1.1 ± 0.1 1.5 ± 0.2 + 33 
2D6 Bufuralol 4´-OH 2.9 ± 0.1 3.2 ± 0.1 + 9 
3A4 Nifedipine Desaturation 2.0 ± 0.6 1.8 ± 0.5 - 10 
19A1 Testosterone Estrone 
formation 
10.8 ± 0.2 10.9 ± 0.9 + 1 
21A2 Progesterone 21-OH 51 ± 10 68 ± 6 + 30 
2A6 Coumarin 6-OH a a - 14 
1A1 Ethoxyresorufin (resorufin) a a + 8 
1A2 Ethoxyresorufin (resorufin) a a + 26 
1B1 Ethoxyresorufin (resorufin) a a - 4 
 
Position of hydroxylation (OH) or product indicated. 
a Assayed using fluorescence methods but absolute amounts of product not calibrated. 
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Figure 14. Stimulation of P450 4A11 Variants of Lauric Acid ω-Hydroxylation Activity 
by DTT. A, wild-type P450 4A11 (CYP4A11*1); B, F434S variant (rs1126742).  
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3.2.2. Oxidative Inhibition of P450 4A11 
P450 4A11 hydroxylation activity was inhibited by H2O2. This inhibition occurred in a 
time-dependent manner with an 80% loss in activity occurring within 15 minutes (Fig. 15), 
a rate much higher than reported for uncatalyzed sulfenylation of thiols (27). Fifty percent 
activity loss occurred at a concentration of 140 µM H2O2 (Fig. 16).   
3.2.3. Site-directed Mutagenesis 
P450 4A11 encodes eight cysteinyl residues in the translated protein, and five of 
these cysteines were mutated to serine. Cys-457 corresponds to the proximal heme ligand 
and could not be changed (28), and neither C347S nor C375S produced protein with the 
typical P450 difference spectrum (29). Steady-state kinetic assays were done with the 
remaining five cysteine mutants, both with and without DTT pretreatment (Fig. 17). The 
response to DTT was qualitatively the same as the wild-type P450 4A11 (Fig. 14A), except 
for C200S (Fig. 17C) and possibly C513S (Figs. 17A, 17E), but these analyses did not 
implicate any of these five cysteines as being involved in the modulation of hydroxylation 
activity observed in the wild-type enzyme. The major conclusion was that none of these 
five cysteines are critical to the normal activity of P450 450 4A11, leaving only the non-
mutated Cys-347, Cys-375, and Cys-457 as candidates for the oxidation-reduction 
phenomenon. These analyses were performed by Donghak Kim.  
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Figure 15. Kinetics of Loss of Lauric Acid ω-Hydroxylation Activity of P450 4A11 in 
the Presence of H2O2. P450 4A11 (500 nM) was incubated with 500 µM H2O2 in “oxidation 
buffer” (Chapter II) (pH 8.0) for the indicated times. Residual H2O2 was removed by 
treatment with human erythrocyte catalase (50 units/ml) for 10 minutes, and lauric acid ω-
hydroxylation activity was measured in a reconstituted enzyme system. The initial 
(uninhibited) rate was 26.9 nmol ω-hydroxylation activity lauric acid formed min-1 (nmol 
P450)-1. 
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Figure 16. Loss of P450 4A11 Lauric Acid ω-Hydroxylation Activity as a Function of 
H2O2. P450 4A11 (500 nM) was incubated with varying concentrations of H2O2 for 15 min 
at 37 °C in oxidation buffer (pH 8.0). Catalase (10 units/ml) was added to quench the 
residual H2O2 (for 10 min at 25 °C), and the remaining P450 4A11 was reconstituted and 
used to measure lauric acid ω-hydroxylation activity. Results are presented as means ± 
SD of triplicate experiments. The outer lines indicate 95% confidence intervals.   
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Figure 17. Lauric Acid ω-Hydroxylation Activity of Cys→Ser Mutants of P450 4A11. 
For experiments done at the same time with wild-type P450 4A11, see Fig. 2A. Assays 
were done in the absence () and presence () of 1 mM DTT, as indicated. A, C43S; B, 
C86S; C, C200S; D, C255S; E, C513S. 
  
62 
 
3.2.4. Identification of a Sulfenic Acid 
A portion of oxidized P450 4A11 treated with each of several different 
concentrations of H2O2 was treated with d6-dimedone (co-incubation) and subsequently 
counter-alkylated with (d0-) iododimedone (30) (Fig. 10). The alkylated protein was 
digested with trypsin and analyzed by LC-MS/MS; integrated areas of extracted ion 
chromatograms for the heavy (sulfenic acid-modified) and light (free thiol) were compared 
using the program Skyline (31). The peptide containing Cys-457 was found to be 
sulfenylated. (Fig. 18). Sulfenylation of (the heme-thiolate ligand) Cys-457 coincided with 
the attenuation of enzymatic activity observed with increasing concentrations of H2O2 (Fig. 
19).  Oxidation of the heme-thiolate ligand would lead to an inability of the heme iron to 
effectively activate oxygen and carry out catalysis. 
Additionally, cysteines other than Cys-457 were found to be sulfenylated, but 
overall were less modified, in general, than the heme-thiolate ligand (Fig. 20). These 
peptides were positively identified by MS/MS fragmentation (Fig. 21).  
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Figure 18. MS/MS Fragmentation of Cys-457 Containing Peptide of 4A11. Annotated 
HCD MS/MS of the heme-thiolate containing peptide (456-NCIGK-460) alkylated with d0-
dimedone (A) or d6-dimedone (B). 
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Figure 19. Formation of a Sulfenic Acid in Cys-457 (Heme Thiol Group) as a Function 
of H2O2 Concentration. P450 4A11 samples were labeled with d6-dimedone and counter-
alkylated with d0-iododimedone at varying concentrations of H2O2. Labeled protein was 
then subject to trypsin digestion and LC/MS/MS analysis. Masses corresponding to Cys-
457 deuterated and non-deuterated peptides were extracted, and the resulting areas were 
integrated using Skyline software. A, bar graphs of comparisons of peak areas for CySH 
peptide (red) and Cys-OH peptide (blue); raw peaks for CySH peptide (red) and Cys-OH 
peptide (blue) (not normalized in each case). 
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Figure 20. Quantitation of Sulfenylated Cysteines of P450 4A11. Graph of quantitated 
peptides containing P450 4A11 pre-incubated with H2O2 with ratios of sulfenylation 
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Figure 21. Iododimedone-labeled Peptides of P450 4A11. Annotated spectra of tryptic 
peptides. A, Cys-53; B, Cys-86; C, Cys-200, D, Cys-255; E, Cys-347. Peaks are annotated 
with: b- (red) and y-series (blue) ions; neutral losses and a-series ions (green). Spectra 
were annotated using Scaffold (205). 
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This sulfenylation, however, did not exclude the possibility for thiol oxidation to 
occur in the form of intra- or intermolecular disulfide bonds for other P450 4A11 thiols.  An 
ICAT approach was developed using d5/d0-iodoacetanilide (206,207) (Fig. 10). Briefly, 
samples were treated with varying concentrations of H2O2 and thiols were then trapped 
using a trichloroacetic acid precipitation (208). Protein was then pelleted by centrifugation, 
resuspended, and treated with d5-iodoacetanilide to alkylate free thiols (209). The protein 
was then precipitated and resuspended in reducing buffer to reduce disulfide bonds (and 
any unreacted sulfenic acids) and alkylated with d0-iodoacetanilide. Tryptic peptides were 
analyzed via LC-MS/MS and the area ratios of alkylated deuterated/non-deuterated thiol 
containing peptides were analyzed. This experiment showed no differences in ratios 
between a reduced P450 4A11 protein control and up to 1 mM H2O2 (Fig. 22). Seven of 
the eight cysteines in P450 4A11 maintained at least 60% reduction (i.e. >60% d0 labeling) 
with only Cys-513, the carboxy-terminal cysteine, being oxidized further with increasing 
H2O2. 
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Figure 22. Quantitation of Oxidized Cysteines of P450 4A11. Graph of quantitated 
peptides containing P450 4A11 pre-incubated with H2O2 with ratios of iodoacetanilide 
labeling.  
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3.2.5. Spectral Analysis of Heme-thiolate Oxidation 
Spectral properties of P450 4A11 were used to further address the proteomic 
results, i.e. to confirm the hypothesis that the sulfenic acid moiety is disrupting the iron 
coordination of the heme, TCEP-treated P450 4A11 was treated with H2O2, reconstituted 
with NADPH-P450 reductase, deaerated, and placed under an anaerobic atmosphere of 
CO. Following the addition of NADPH, spectra were recorded for TCEP-reduced (Fig. 9A) 
and H2O2-oxidized (Fig. 23) P450 4A11. The H2O2-oxidized protein showed increased 
absorbance at 420 nm for the CO-bound form. Sodium dithionite was added to these 
samples, which increased the absorbance of the oxidized enzyme at 450 nm and 
decreased the absorbance at 420 nm. NADPH-P450 reductase is able to reduce ferric 
heme to the ferrous state (allowing CO binding) but cannot reduce the sulfenic acid, 
leading to an inactive protein due to the loss of the thiolate axial coordination. However, 
dithionite is able to reduce a sulfenic acid (210), allowing for the reduced thiolate to re-
ligand with the heme-iron (Fig. 6). 
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Figure 23. Reduction of P450 4A11 by NADPH-P450 Reductase and Sodium 
Dithionite in the Presence of CO. Reduced protein (A) and protein oxidized with 500 µM 
H2O2 (B) was deaerated and placed under an anaerobic CO atmosphere. NADPH was 
then added, and absorbance spectra was recorded (blue). Dithionite was then added 
(red). 
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3.2.6. Sulfenylation of Family 4 P450 Enzymes in a CYP4A11tg Mouse Model 
To determine if this oxidative modification of P450 4A11 occurs in vivo, a CYP4A11 
transgenic mouse model was used (174). Liver and kidney tissues from four male mice 
were harvested and subcellular fractionation was done immediately. Microsomes were 
obtained within three hours of tissue harvesting via differential centrifugation and, as with 
the recombinant protein, incubated with either buffer, d6-dimedone, or d6-dimedone 
supplemented with 500 µM H2O2 (Fig. 10). These labeled samples were then treated with 
catalase, reduced, counter-alkylated with (d0-) iododimedone, and digested with 
chymotrypsin. Chymotrypsin was used to produce peptides containing the heme-ligand 
cysteine unique to both P450s 4A11 and 4a12 in kidneys of male mice (Fig. 11) (211). 
The microsomal chymotryptic peptides were analyzed via LC-MS/MS and the resulting 
peak area ratios were quantitated.  
The heme-thiolate Cys-457 of P450 4A11 showed ~ 75% dimedone labeling 
(sulfenylation) in both the dimedone and H2O2-supplemented samples in the kidney 
microsomes of three mice and ~40% labeling in the liver microsomes (Figs. 24A, 24B, 
25). One mouse was considerably younger (age of six weeks at time of harvest) and the 
expression of P450 4A11 was greatly diminished compared to the older mice (3 months 
(2) and 7 months). Interestingly, mouse P450s 4a12 (Fig. 24C, 24D, 26) and 4b1 (Fig. 
24E, 27) also showed significant sulfenylation of the respective heme-thiol ligands. 
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Figure 24. Analysis of Human and Mouse P450 Peptides in tg4A11 Mice.   
74 
 
 
Figure 25. Iododimedone-labeled Peptide of P450 4A11 in Mouse Tissue Sample. 
Annotated spectra of the chymotryptic peptide containing Cys-457 alkylated with d0-
iododimedone (A) and d6-dimedone (B) from mouse tissue. A representative extracted 
ion chromatogram showing the [M+2H] and [M+3H] ion species used for MS1 precursor 
quantitation in Skyline (B, Inset). HCD fragmentation produced doubly dissociated 
internal fragments which were considered to be diagnostic. Spectra were annotated 
using Protein Prospector MS-Product (http://prospector.ucsf.edu) (212). All annotated 
fragments have m/z values <10 Δppm from predicted fragment.  
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Figure 26. Evidence of P450 4a12 Sulfenylation of Heme-Thiolate Ligand.  Annotated 
spectra of the chymotryptic peptide containing Cys-455 alkylated with d0-iododimedone 
(A) and d6-dimedone (B) from mouse tissue. A representative extracted ion chromatogram 
showing the [M+2H] and [M+3H] ion species used for MS1 precursor quantitation in 
Skyline (B, Inset). HCD fragmentation produced doubly dissociated internal fragments 
which were considered to be diagnostic. Spectra were annotated using Protein Prospector 
MS-Product (http://prospector.ucsf.edu) (212). All annotated fragments have m/z values 
<10 Δppm from predicted fragment. 
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Figure 27. Evidence of P450 4b1 Sulfenylation of Heme-Thiolate Ligand.  Annotated 
spectra of the chymotryptic peptide containing Cys-452 alkylated with d0-iododimedone 
(A) and d6-dimedone (B) from mouse tissue. A representative extracted ion chromatogram 
showing the [M+2H] ion species used for MS1 precursor quantitation in Skyline (B, Inset). 
Spectra were annotated using Protein Prospector MS-Product (http://prospector.ucsf.edu) 
(212). All annotated fragments have m/z values <10 Δppm from predicted fragment. 
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3.3. Discussion 
I have shown that H2O2 reacts with the heme-thiolate cysteine of P450 4A11 to 
form a sulfenic acid and disrupt the iron-sulfur coordination. Five of the eight Cys residues 
in the protein were shown not to be essential for activity (Fig. 17), and the heme proximal 
ligand Cys-457 was identified as the major site of oxidation by modification and proteomic 
analysis (Figs. 18, 19).  It is well-established that breaking this bond will also convert P450 
to an inactive form, cytochrome P420 (213,214). The accessibility of the heme thiolate 
ligand has been established in studies with mercurials, as well as the conversion to the 
inactive cytochrome P420 (215,216). 
The concentration of H2O2 required to inhibit P450 4A11 (Fig. 16) is within a 
physiological range (217) and was shown to be reversible via reduction by thiols (Fig. 12, 
13, 14). P450 enzymes are known to produce H2O2 in conjunction with NADPH-P450 
reductase and NADPH, with or without substrate present (218). H2O2 production was 
measured (218) for a typical reaction containing 0.2 μM P450 4A11, 0.4 μM NADPH-P450 
reductase, the NADPH-generating system, and 100 µM lauric acid and determined to be 
5 µM min-1, i.e. 25 nmol H2O2 produced min-1 (nmol P450 4A11)-1(Fig. 28). Typical 
incubations with lauric acid or arachidonic acid are conducted for two to five minutes, and 
the concentration of H2O2 produced should be negligible in proportion to the amount 
needed to inhibit the enzyme (Fig. 16).  
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Figure 28. Rate of H2O2 Formation by P450 4A11. Rate of Formation (Background 
Subtracted) = 5.1 µM/min-1. Adjusted for P450 concentration (200 nM) = 25 min-1 
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Thiol activation is common in in vitro (219). The activation seen in the case of P450 
4A11 was considerably higher than with any other P450s tested (Table 3), indicating that 
this redox sensitivity is rather unique among the human P450s tested. Although numerous 
P450 purification protocols include dithiothreitol or β-mercaptoethanol (220,221), it is not 
clear that this is necessary in most cases.  
Oxidation of P450 4A11 with H2O2 led to an attenuation of enzymatic activity (Figs. 
12, 13, 14). This loss of activity was correlated with an increased observation of dimedone 
alkylation (sulfenylation) at Cys-457, the heme-thiolate ligand (Figs. 18, 19). Sulfenic acid 
modifications have been directly implicated in the regulation of numerous enzymatic 
processes including GAPDH, peroxiredoxin, EGFR, and others (222). However, sulfenic 
acid formation involving disruption of heme-iron coordination is unprecedented to our 
knowledge. Choudhury et al. (223) mutated the cytochrome c peroxidase distal histidine 
ligand to a cysteine and observed a cysteic acid (cysteine sulfonic acid) in a crystal 
structure of the cysteine mutant, with a sulfonate oxygen coordinated to the heme. They 
observed activity but it was markedly lower than that of the unmodified enzyme. These 
results were interpreted as the heme iron itself oxidizing the cysteine, as a substrate. This 
is an appropriate conclusion, in that peroxidases generally have non-Cys heme ligands 
(224,225). Nitrile hydratase enzymes are known to coordinate iron or cobalt with both 
sulfenylated and sulfinylated thiols; additionally, the sulfenic acid is essential for the 
formation of the carbamate product (226). Our results do not discern whether the 
sulfenylated thiol is still (weakly) coordinated to the heme or if the coordination completely 
disrupted in P450 4A11. Dimedone, however, can react with sulfenamides as well as 
sulfenic acids (227) which would provide similar results in these experiments as sulfenic 
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acid. If a sulfenamide was indeed the cause of this redox modulation, generally thiol 
oxidation to sulfenic acid would occur first followed by subsequent condensation with a 
backbone nitrogen to form the sulfenamide (227). 
ICAT analysis with iodoacetanilide did not provide evidence for a disulfide bond. 
α-Haloketones react with sulfenic acids to form sulfoxides (133), so these peptides would 
not be quantified in a direct analysis between d0/d5-alkylated peptides because the m/z 
value would increase by 16, the mass of oxygen. Inaccuracy could also be due to further 
di- and tri-oxidation (SO2 and SO3 respectively) of cysteines.  Cys-513 appeared to be the 
only thiol oxidized to a large extent in our analysis, although the exact nature is unknown. 
Additionally, Cys-347 and Cys-375 appear to have proximity to each other in the homology 
model (Fig. 29). The inability to express the mutated forms of these two cysteines indicates 
that they are important for structural and/or conformational integrity, but our ICAT analysis 
did not indicate that either thiol is oxidized. This may suggest slight structural differences 
between human P450 4A11 and rabbit P450 4B1. 
Taken together the mutant analysis, dimedone labeling, and ICAT labeling 
methods show that cysteines other than Cys-457 are oxidized in P450 4A11 but do not 
appear to directly inactivate the protein or are correlated with the loss of activity. The 
oxidation or mutation of these ancillary cysteines could produce slight conformational 
changes, but these changes would not produce the spectral change at 450 nm that 
sulfenylation of Cys-457 does.   
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Figure 29. Homology Model of P450 4A11 Based on Crystal Structure of Rabbit P450 
4B1. (228). Cys residues are shown, as are Asn-456, Lys-460 and Phe-462.  
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Detection of sulfenylation in mouse kidneys and livers provides a physiological 
context for this modification. The high percentage of dimedone alkylation seen in the P450 
4A11, 4a12, and 4b1 heme peptides was surprising in that this would imply that a large 
percentage of the Family 4 P450 enzymes is constitutively inactive in the kidney. One 
possible explanation could be that, since 20-HETE is a very potent vasoconstrictor with 
submicromolar activity (229,230), these enzymes are very tightly regulated and 
sulfenylated enzymes could act as a reserve mechanism. Conversely, if an increase in 
vascular tone is required quickly, Family 4 P450 enzymes could be reduced quickly and 
be available for production of 20-HETE. P450 4A11 sulfenylation was observed to a lesser 
degree in liver. This may be due to the larger reducing potential in GSH stores the liver 
has compared to the kidney (231).   
One unique feature of Subfamily 4A P450 enzymes is the covalent binding of the 
heme prosthetic group to the enzyme through a conserved glutamic acid residue 
(232,233). This unique feature may allow for easier re-coordination of the reduced thiol 
with an immobilized heme iron. In recombinant P450 4A11 it is reported that approximately 
25% of the enzyme has covalently bound heme (233), but the fraction has not been 
determined in human samples. Rodent Subfamily 4A P450 enzymes have higher 
percentages of heme covalently bound to the enzyme (233). LeBrun et al. (233) have 
suggested that this covalent binding may contribute to differences in substrate binding 
rates and enzymatic regioselectivity.  
A recent crystal structure of recombinant rabbit P450 4B1 shows complete 
adduction of the heme through a bond between a heme methyl group and Glu-310 
(analogous to Glu-321 in P450 4A11) (228). In examining the alignment of mouse P450 
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4b1 and rabbit P450 4B1 (uniport.org), these two enzymes share 86% identity and 95% 
similarity. A modeled structure shows a relatively open conformation on the proximal side 
of the protein (Fig. 29). Cysteines that were mutated in this study are located in the 
peripheries of the protein, away from the proposed active site, and likely do not influence 
enzyme function.  
Disruption of the iron-sulfur coordination would alter the absorbance properties of 
P450 4A11 (Fig. 23). Under an anaerobic CO atmosphere, NADPH-P450 reductase can 
reduce ferric heme to its ferrous state, allowing CO to bind. This CO-bound state has 
absorbance with λmax at 450 nm if the heme-thiolate ligand is intact. When this coordination 
is disrupted (via sulfenylation in this case), the CO-binding spectrum was shifted to a λmax 
at 420 nm (Fig. 23). Interestingly, the addition of dithionite after reduction with NADPH-
P450 oxidoreductase reduces the sulfenic acid (210) and allows for re-coordination of the 
thiolate-heme complex. The observation of a sulfenylated heme-thiolate ligand has 
probably been overlooked previously because of the common laboratory practice of 
determining P450 concentration using dithionite as the reducing agent for obtaining P450 
difference spectra.   
In summary, P450 4A11 seems to show a unique activation under reducing 
conditions compared to other P450 enzymes tested. Conversely, H2O2 inhibits the 
enzymatic activity of the enzyme. Sulfenic acid formation of the heme thiolate ligand was 
detected by labeling and LC-MS analysis (Figs. 18, 19) and was verified spectrally (Fig. 
23). The physiological relevance of the modification was demonstrated with the 
identification of sulfenylated P450s in freshly isolated mouse kidneys and livers. This 
modification is a potentially important observation that may have implications in other 
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P450s, as shown by our results with the mouse P450 4a and 4b enzymes. Sulfenylation 
could provide for biological regulation of P450 4A11 and its production of the potent 
vasoconstrictor 20-HETE. As mentioned previously, 20-HETE has been shown to induce 
ROS formation as well as play an important role in blood pressure control, which is known 
to be mediated by ROS production (157).  The extent of sulfenylation of 4A/a P450 
enzymes in tissues may provide a mechanism to greatly reduce the production of 20-
HETE. 
This finding led to the hypothesis that other P450s are also redox regulated and 
this sensitivity may function to regulate xenobiotic metabolism. I began testing this 
hypothesis and those results can be found in Chapter IV.  
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Chapter IV 
4. Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other 
Drug Metabolizing Enzymes as a Response to Redox Alteration 
4.1. Introduction 
Following the results, I acquired in Chapter III, I decided to further investigate these 
LC-MS/MS DDA data which indicated that P450s in other subfamilies were also 
sulfenylated in a similar fashion to the P450 4 family (Table 4). This result required further 
testing which resulted in another body of work. Initially, I repeated the dimedone-labeling 
experiment in human liver and kidney microsomes. The results from this study indicated 
that human P450 enzymes were also sulfenylated in a similar fashion as one found in 
mice. Interestingly, many other drug metabolizing enzymes showed sulfenic acid 
formation, suggesting redox regulation.  
I decided to focus on drug metabolizing P450 enzymes specifically in the P450 
Subfamilies 1A, 2C, 2D, and 3A. Enzymes in these classes are involved in the metabolism 
of the majority of xenobiotic compounds the human body is exposed to. These enzymes 
were readily available in this laboratory for testing.  
I performed identical experiments with these enzymes as I had done in Chapter III 
(see Chapter II for methods). The results from the P450 subfamilies mentioned above 
indicated that P450s likely have three separate redox classes: (1) redox insensitive, (2) 
heme-thiolate sensitive, and (3) ancillary thiol sensitive. This differential redox sensitivity 
likely translates to a phenotype previously observed in vivo in which the mechanism has 
not been elucidated.  
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Shared peptide sequences: 1STGKRICAGEGLARMELF, 2 LFFTCLLQRF 
Table 4. Sulfenylated Mouse Microsomal Proteins. Proteins with respective gene 
names identified in microsomes of mouse livers and kidneys at 5% peptide FDR. 
Modifications are presented as cysteine (C) and sequence location. Tissue location is 
denoted as liver (L) or kidney (K) by the modification. 
 
  
Description 
Gene 
Name 
Modification 
Carboxylesterase 3B Ces3b C434 (L) 
Cytochrome P450 1a2 Cyp1a2 C404 (L) 
Cytochrome P450 2c29 Cyp2c29 
C435 (L)1, C216 (L), C226 (L), 
C372 (L) 
Cytochrome P450 2c50 Cyp2c50 C435 (L)1 
Cytochrome P450 2c54 Cyp2c54 C435 (L)1 
Cytochrome P450 2d10 Cyp2d10 C462 (L), C496 (L) 
Cytochrome P450 2d26 Cyp2d26 C462 (L/K)2, C496 (L) 
Cytochrome P450 2d9 Cyp2d9 C462 (L/K)2, C496 (L) 
Cytochrome P450 2e1 Cyp2e1 C488 (L/K) 
Cytochrome P450 2f2 Cyp2f2 C487 (L) 
Cytochrome P450 3a11 Cyp3a11 
C64 (L), C443(L), C98(L), 
C239(L) 
Cytochrome P450 4a12A Cyp4a12a C373 (L/K) 
Cytochrome P450 4b1 Cyp4b1 C453 (K), C369 (K), C373 (K) 
Leukotriene-B4 ω-hydroxylase 2 Cyp4f3 C384 (L) 
Dimethylaniline monooxygenase, N-
oxide-forming 2 
Fmo2 C146 (K) 
Dimethylaniline monooxygenase, N-
oxide-forming 5 
Fmo5 C248 (L), C468 (L) 
Epoxide hydrolase 1 Ephx1 C312 (L) 
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4.2. Results 
4.2.1. Identification of Sulfenylated P450s in Mouse Microsomes 
Following my report that identified oxidation of P450 Subfamily 4a enzymes in 
mouse kidney and liver microsomes (112), further analysis led to the identification of other 
sulfenylated cysteines in other P450s in Subfamilies 2, 3, and 26 (Table 4). Of these, the 
mouse P450 3a, 2c, 2d, and 2e proteins are known drug metabolizing enzymes in mice 
(234). These results indicate that many P450s may be inhibited by oxidative 
posttranslational modification of cysteines. 
4.2.2. Identification of Sulfenylated Drug Metabolizing Enzymes in Human Kidney and 
Liver Microsomes 
The mouse results (Table 4) led to the expansion of the proteomic study to human 
microsomes. Frozen human kidney and liver tissues from five individuals were rapidly 
fractionated into microsomal fractions in deaerated buffer and labeled using an isotope-
coded ICDID strategy for relative quantitation (Fig. 10) (32). After excising the 40-60 kDa 
P450 region and digesting the proteins with trypsin, I identified 347 modified proteins in 
the kidney microsomes at a 5% peptide false discovery rate (FDR) (Table 5, Fig. 30). In 
addition, 380 modified proteins were identified in the liver microsomal fractions (5% 
peptide FDR, Table 5, Fig. 30). Of these proteins, 11 P450s were sulfenylated in the 
kidney microsomes and 24 P450s in liver microsomes. The identified P450s included 
enzymes that are important in the metabolism of both endogenous and xenobiotic 
substrates.  
In addition to the P450 enzymes, other modified proteins were identified that are 
important in drug metabolism, including UDP-glucuronosyltransferases (UGT), epoxide 
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hydrolase, flavin-containing monooxygenases (FMO), monoamine oxidases (MAO), and 
carboxylesterases. Other previously known sulfenylated proteins were also identified 
including protein disulfide isomerases (33) and aldehyde dehydrogenases (34). MS1 
precursor intensities for peptides were quantified using Skyline software (26). 
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Table 5. Sulfenylated Human Microsomal Proteins. Proteins with respective gene 
names identified in microsomes prepared from human livers and kidneys, at 5% 
peptide FDR. Modifications are presented as cysteine (C) and sequence location.  
Description Gene 
Name 
Modifications Found in Liver  Modifications Found in 
Kidney 
Arylacetamide 
deacetylase 
AADAC C340 
(28±5%) 
   --  
Alcohol dehydrogenase 
1A 
ADH1A C1331 
(32±2%) 
C1122 
(35±4%) 
C2413 
(37±3%) 
C328 
(31±6%) 
C98 
(29±8%) 
C196 
C1714 
C1754 
C212 
C47 
--  
Alcohol dehydrogenase 
1B 
ADH1B C47 
(27±3%) 
C985 
(34±2%) 
C1331 
C1122 
C2413 
C1714 
C1754 
C1966 
C2126 
 --  
Alcohol dehydrogenase 
1C 
ADH1C C1122 C985 C1967 C2413 --  
Alcohol dehydrogenase 4 ADH4 C246 
(28±2%) 
C274 
(39±5%) 
C47 
(35±3%) 
C23 
(37±4%) 
C99 
(32±4%) 
C105 
C287 
C2016 
C2176 
 --  
Alcohol dehydrogenase 6 ADH6 C1967    --  
Aldehyde dehydrogenase 
family 16 member A1 
ALDH16A1 C350    C496  
Aldehyde dehydrogenase 
family 1 member A3 
ALDH1A3 --    C196 C197 
Aldehyde dehydrogenase, 
mitochondrial 
ALDH2 C386 
(33±3%) 
C66 C472  C66 C472 
Aldehyde oxidase AOX1 --    C386 
(23±13%) 
C179 
Liver carboxylesterase 1 CES1 C285 
(40±3%) 
C274 
(37±5%) 
C390 
(37±1%) 
 
C116 
(37±3%) 
 C390  
Steroid 17-α-
hydroxylase/17,20 lyase 
CYP17A1 --    C442  
P450 1A2 CYP1A2 C504 
(42±5%) 
C159 
(44±5%) 
  --  
P450 26A1 CYP26A1 --    C170  
Sterol 26-hydroxylase, 
mitochondrial 
CYP27A1 C228 
(36±6%) 
C427 
(43±1%) 
  C228  
P450 2A6 CYP2A6 C82 
(34±4%) 
C439 
(36±3%) 
  --  
P450 2B6 CYP2B6 C436 
(32±3%) 
C180 
(27±7%) 
C152 
(46±2%) 
C79 --  
P450 2C18 CYP2C18 C3388 
(42±2%) 
C1519 
(38±2%) 
C216 
(38±4%) 
C486 C2661
0 
 
--  
P450 2C19 CYP2C19 C3388 
C435 
C372 
(40±4%) 
C26610 
C216 
C179 
C1519 --  
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Description Gene 
Name 
Modifications Found in Liver  Modifications Found in 
Kidney 
P450 2C8 CYP2C8 C435 
(37±3%) 
C1519 
(41±3%) 
C51 
(34±2%) 
C26610 
(39±3%) 
C486 
(37±4%) 
C3388 
C216 
C225 
C179 
C172 
C175 
C164 
C26610  
P450 2C9 CYP2C9 C372 
(38±1%) 
C486 
(38±2%) 
C266 
(41±5%) 
C216 
(38±3%) 
C172 
C164 
C179 
 
C3388 
C1519 
 
C1519 C216 
P450 2D6 CYP2D6 C443 
(45±7%) 
C191 
(39±4%) 
C57 
(27±7%) 
 --  
P450 2E1 CYP2E1 C261 
(39±6%) 
C437 
(37±3%) 
C488 
(34±2%) 
C268 
(42±2%) 
C480 
(39±4%) 
 --  
P450 3A4 CYP3A4 C9811 
(33±1%) 
C46812 
(40±2%) 
C58  --  
P450 3A5/3A7 CYP3A5/A
7 
C9811 C46712   --  
P450 4A11 CYP4A11 C25613 
(40±2%) 
C53 
(36±5%) 
C200 
(33±4%) 
C86 
(36±4%) 
C51314 
 
C375 C25613 
(41±5%) 
C200 (38±6%) 
C86 
C51314 
P450 4A22 CYP4A22 C25613 C51314   C25613 C51314 
P450 4F11 CYP4F11 C354 
(36±2%) 
C5016 
C46817 
(43±6%) 
C102 
(84±5%) 
C38418* 
C276 
C260 C38418*  
P450 4F12 CYP4F12 C35415 C46817 C384 C5016 --  
P450 4F2 CYP4F2 C102 
(37±2%) 
C384 
(43±13%
) 
C5019 
(36±6%) 
 
C35415 
 
C468 C35415 
(43±5%) 
C102 
P450 4F22 CYP4F22 C5819    --  
P450 4F3 CYP4F3 C35415 
C50 
(38±2%) 
C402 
 
C38418* C4681
7 
C35415 C38418* 
P450 4F8 CYP4F8 --    C35415 C38418* 
P450 4V2 CYP4V2 C282 
(37±5%) 
C383 
(37±5%) 
C483 
(40±4%) 
C406 --  
P45051A1 CYP51A1 C337 C345 C366 
(31±6%) 
C449 --  
Epoxide hydrolase 1 EPHX1 C80 
(39±1%) 
C182 
(38±1%) 
C304 
(38±7%) 
C232 
(39±2%) 
 C80 (43±4%) 
C182 (41±3%) 
C304 
(46±14%
) 
C232 
Dimethylaniline 
monooxygenase  
[N-oxide-forming] 1 
FMO1 --    C63 (43±4%) 
C423 
C111 
(33±3%)  
Dimethylaniline 
monooxygenase  
[N-oxide-forming] 3 
FMO3 C170 
(38±1%) 
C397 
(36±1%) 
C146 
(36±4%) 
C466 
(43±4%) 
C197 
(41±2%) 
 
C68 
(37±3%) 
C294 
(36±9%) 
C21 
C30 
C294  
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Description Gene 
Name 
Modifications Found in Liver  Modifications Found in 
Kidney 
Dimethylaniline 
monooxygenase  
[N-oxide-forming] 5 
FMO5 C112 
(35±4%) 
C248 
(28±0%) 
C468 
(29±10%
) 
C31 
C147 
C22 
 --  
Amine oxidase [flavin-
containing] A 
MAOA C37421* 
(39±2%) 
C20120 
(35±1%) 
C165 
(32±1%) 
 
C306 
(31±2%) 
C266 C20120 
(40±4%) 
C37421*(42±4
%) 
C165 
C266 
Amine oxidase [flavin-
containing] B 
MAOB C156 
(36±1%) 
C297 
(37±1%) 
C36521* C1922
0 
C297 (37±1%) 
C156 (41±3%) 
C19220 
C36521* 
Serum 
paraoxonase/arylesterase 
1 
PON1 C42 
(29±2%) 
C284   --  
Serum 
paraoxonase/lactonase 3 
PON3 C42 
(38±7%) 
   --  
UDP-
glucuronosyltransferase 1-
4 
UGT1A4 C187 
(37±4%) 
   --  
UDP-
glucuronyltransferase 1-6 
UGT1A6 C176    C176  
UDP-
glucuronyltransferase 1-7 
UGT1A7 --    C174  
UDP-
glucuronyltransferase 1-9 
UGT1A9 --    C153  
UDP-
glucuronyltransferase 2A3 
UGT2A3 --    C31  
UDP-
glucuronyltransferase 
2B10 
UGT2B10 C28122 
(40±4%) 
   --  
UDP-
glucuronyltransferase 
2B15 
UGT2B15 C28322    --  
UDP-
glucuronyltransferase 
2B17 
UGT2B17 C28322    --  
UDP-
glucuronyltransferase 2B4 
UGT2B4 C127 
(28±6%) 
C514   --  
UDP-
glucuronyltransferase 2B7 
UGT2B7 C282 
(35±5%) 
   --  
Shared peptide sequences: 1RFTCR, 2NPESNYCLK, 3ELGATECINPQDYK, 
4VCLIGCGFSTGYGSAVNVAK, 5VIPLFTPQCGK, 6VTPGSTCAVFGLGGVGLSAVMGCK, 
7VTPGSTCAVFGLGGVGLSVVMGCK, 8 SPCMQDR, 9 CLVEELRK, 10DFIDCFLIK, 
11ECYSVFTNR, 12VLQNFSFKPCK, 13ACQLAHQHTDQVIQLR, 14RLPNPCEDKDQL, 
15HPEYQEQCR, 16LQCFPQPPK, 17NCIGQAFAMAEMK, 18EIEWDDLAQLPFLTMCI(/L)K, 
19LRCFPQPPR, 20QCGGTTR, 21I(/L)CELYAK, 22PFLPNVDFVGGLHCK.   
* Single amino acid variation (leucine/isoleucine) in peptide sequences that cannot be determined 
from MS/MS fragmentation. 
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Figure 30. Quantitation of Sulfenylated Human Microsomal Proteins. Percent 
sulfenylation of cysteine (C) containing peptides for each protein in liver samples (closed 
circle) and kidney samples (open circle) represented with mean value (black line). 
Superscripts denote shared peptide sequences: 1RFTCR, 2NPESNYCLK, 
3ELGATECINPQDYK, 4VCLIGCGFSTGYGSAVNVAK, 5VIPLFTPQCGK, 
6VTPGSTCAVFGLGGVGLSAVMGCK, 7VTPGSTCAVFGLGGVGLSVVMGCK, 8 
SPCMQDR, 9 CLVEELRK, 10DFIDCFLIK, 11ECYSVFTNR, 12VLQNFSFKPCK, 
93 
 
13ACQLAHQHTDQVIQLR, 14RLPNPCEDKDQL, 15HPEYQEQCR, 16LQCFPQPPK, 
17NCIGQAFAMAEMK, 18EIEWDDLAQLPFLTMCI(/L)K, 19LRCFPQPPR, 20QCGGTTR, 
21I(/L)CELYAK, 22PFLPNVDFVGGLHCK.  * denotes a single amino acid variation 
(leucine/isoleucine) in peptide sequences that cannot be determined from MS/MS 
fragmentation. 
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4.2.3. Spectral Analysis of Recombinant P450s for Thiol Sensitivity to H2O2 
P450s 1A2, 2C8, 2D6, and 3A4 were selected for further analysis. To confirm that 
these P450 enzymes were affected by sulfenylation, we utilized their spectral properties 
to determine if heme coordination or interaction with NADPH-P450 reductase was 
disrupted. In the presence of CO, disruption of the heme thiol ligation either prevents 
reduction of the heme or yields the inactive form, cytochrome P420 (the five-coordinate 
ferrous-CO complex of which has a maximal absorbance at P420 nm) so that a 
characteristic 450 nm spectrum is not observed (35). TCEP-pretreated P450s were 
treated with 500 μM H2O2 and (after the removal of residual H2O2 by catalase) 
reconstituted with NADPH-P450 reductase, deaerated, and placed under an anaerobic 
atmosphere of CO. Following the addition of NADPH, spectra were recorded for the 
TCEP-reduced (Fig. 31, left column) and H2O2-oxidized (Fig. 31, right column) samples. 
Sodium dithionite, which reduces both sulfenic acids and the heme iron, was subsequently 
added to both samples (Fig. 6). P450 1A2 was very insensitive to H2O2, with only a slight 
increase in 450 nm absorbance after dithionite addition (Fig. 31A). P450s 2D6 (Fig. 31B) 
and 2C8 (Fig. 31C) both exhibited sensitivity to H2O2-dependent oxidation, with a noted 
decrease in 420 nm absorbance (indicative of the inactive form, cytochrome P420) and 
an increase in 450 nm absorbance indicative of reestablishment of the heme-thiol ligand. 
P450 3A4 (Fig. 31D) exhibited a complete loss of 450 nm absorbance in the oxidized 
sample, which was not reversible upon addition of dithionite and increased absorbance at 
420 nm. 
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Figure 31. Spectral Analysis of Oxidized P450s. Analysis was performed for P450s 1A2 
(A), 2C8 (B), 2D6 (C), and 3A4 (D). POR; P450 Oxidoreductase  
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4.2.4. Oxidative Inhibition of P450 1A2, 2C8, 2D6, and 3A4 Catalytic Activities 
The enzymatic activity of P450 1A2 was largely uninhibited with preincubation of 
up to 1 mM H2O2, using phenacetin O-deethylation as a reaction, consistent with the 
spectral results (Fig. 32A). P450 2C8 showed sensitivity to H2O2, with an approximate IC50 
value of 150 µM and a loss of 87% activity at 1 mM H2O2, using taxol as a substrate (Fig. 
32B).  P450 2D6 was also inhibited by H2O2, with an estimated IC50 value of ~300 µM (Fig. 
32C) and loss of 70% activity at 1 mM H2O2, using dextromethorphan as a substrate. An 
IC50 value of ~300 µM H2O2 was determined for P450 3A4, using testosterone as a 
substrate (Fig. 32D), with a loss of 95% of activity at 1 mM H2O2. 
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Figure 32. Oxidative Inhibition of P450 Catalytic Activity. A, P450 1A2 was incubated 
with the substrate phenacetin, and acetaminophen was monitored as the product. The 
reduced control enzymatic rate was 1.85 ± 0.01 min-1. B, P450 2C8 was incubated with 
taxol, and 6α-hydroxytaxol was monitored as the product. The reduced control enzymatic 
rate was calculated as 5.5 ± 0.4 min-1. C, P450 2D6 was incubated with dextromethorphan 
and dextrorphan was monitored as the product. The reduced control enzymatic rate was 
5.6 ± 0.1 min-1. D, P450 3A4 was incubated with testosterone and 6β-hydroxytestosterone 
was monitored as the product. The reduced control enzymatic rate was 11.3 ± 0.3 min-1. 
Samples were acquired in biological duplicate and presented as means ± SD (range). 
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4.2.5. Sulfenylation of P450s 1A2, 2C8, 2D6, 3A4 
P450s 1A2, 2C8, 2D6, and 3A4 were subjected to ICDID labeling followed by LC-
MS/MS analysis of tryptic peptides (Fig. 10). For P450 1A2, this assay allowed three of 
the seven cysteines to be quantified (Fig. 33A, APPENDIX A1). Cys-458 (heme-thiol 
ligand) and Cys-504 showed low levels of sulfenylation up to 1 mM H2O2. Additionally, 
Cys-159 showed very high levels of oxidation, but this did not impair the enzymatic activity 
of P450 1A2 (Fig. 32A,33A), indicating that P450 1A2 is insensitive to thiol oxidation.  
Five thiol-containing peptides were quantified for P450 2C8 (Fig. 33B, APPENDIX 
A2). Cys-338, Cys-51, Cys-151 and Cys-435 (heme-thiol ligand) were sulfenylated in a 
H2O2-dependent manner, while Cys-266 was oxidation insensitive.  
Two peptides of P450 2D6 could be quantified (Fig. 33C, APPENDIX A3). Cys-
443 (heme-thiol ligand) showed a H2O2-dependent increase in sulfenylation compared to 
the reduced control.  
P450 3A4 ICDID labeling allowed for the quantitation of four of the seven cysteines 
(Fig. 33D, APPENDIX A4). The heme-thiol cysteine (Cys-442) showed a significant H2O2-
dependent increase in sulfenylation. Cys-468 also showed a H2O2-dependent increase in 
sulfenylation, but peptides containing the di- and trioxidized cysteine sulfinic (SO2-) and 
sulfonic (SO3-) acids (respectively) were also found (Fig. 34, APPENDIX A5), suggesting 
that Cys-468 is very sensitive to oxidation. 
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Figure 33. Sulfenylation of P450 Enzymes. Prereduced enzyme was coincubated with 
d6-dimedone and varying concentrations of H2O2 or TCEP. Proteins were then reduced, 
and counter alkylated with d0-iododimedone. Labeled samples were then subjected to LC-
MS/MS analysis and heavy/light ratios were quantified as described in the experimental 
procedures. Peptides for P450 1A2 (A), 2C8 (B), 2D6 (C), and 3A4 (D) were acquired in 
biological duplicate and presented as means ± SD. 
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Figure 34. Hyperoxidation of P450 3A4 Cys467. Areas for cysteine-containing peptide 
VLQNFSFKPCK modified with d0-iododimedone (SH), d6-dimedone (SOH), sulfinic acid 
(SO2-), and sulfonic acid (SO3-) were normalized to areas for a proteotypic 3A4 peptide 
and each area is reported as a percentage of the summed total of the four modified 
peptides.  
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4.3. Discussion 
ICDID labeling of mouse liver and kidney microsomes provided the interesting 
finding that P450s other than the Family 4 enzymes previously described (112) also 
contained oxidatively modified cysteines. This result may seem inconsistent with previous 
activation studies involving other P450s and DTT, which found no significant differences 
in enzymatic rates (112). However, this is probably because it is a regular practice to 
dialyze against buffer containing dithiothreitol when removing imidazole after His6-
nitrilotriacetic acid/nickel (NTA-Ni2+) purification and storage. P450 4A11 is unusual in its 
ability to readily oxidize in the presence of air, at least under these conditions. This labeling 
strategy was then expanded to human liver and kidney microsomes. Many other P450s 
were found to be sulfenylated in these samples (Table 4). While our knowledge of 
transcriptional regulation, sequence variation, and inhibition is extensive for many P450s 
(9), information about post-translational regulation of P450s is limited, with research 
mostly focused on glycosylation, phosphorylation, ubiquitination, and nitration (198,235). 
Cysteine oxidation may play a role in physiological post-translational regulation as well.  
Cysteine sulfenylation was found in a total of 57 drug metabolizing enzymes. The 
group includes UGTs, FMOs, and carboxylesterases, suggesting that many microsomal 
enzymes are modified by oxidation. These results seem reasonable, in that many 
enzymes have been found to be regulated by oxidation to form cysteine sulfenic acids 
(123,236). Additionally, a comparison of the results presented here and a recent study on 
sulfenylated proteins (127) revealed that 21% (kidney microsomes) and 14% (liver 
microsomes) of proteins were identified in both datasets. This comparison may indicate 
that the RKO adenocarcinoma cell line studied by Gupta et al. (38) likely has similar basal 
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proteins that are oxidized. More in-depth studies of the non-P450 enzymes will be required 
to further verify sensitivity of catalytic activity to oxidation and effects that oxidation may 
have on activity and regulation.  
Relative quantitation of the modified cysteines (Table 4, Fig. 30) yielded similar 
levels of d6-dimedone labeling, which may be due in part to the one-hour incubation time 
with microsomes. While dimedone has been shown to be selective, the low reactivity of 
dimedone with sulfenic acids requires extended incubation times to achieve sufficient 
labeling (rate of 0.8 min-1 under the reported conditions) (146,195). The modified cysteines 
identified are likely sensitive to oxidation, but the amount of labeling observed may be 
representative of the equilibrium of a saturated system.  Overall, 35% and 33% of all 
cysteine-containing peptides identified were modified with d6-dimedone in kidney and liver 
microsomes, respectively. Since more than half of the peptides identified were not 
sulfenylated, the likelihood that this observation is an artifact would seem to be low. 
Furthermore, a control experiment was performed in which kidney and liver tissues were 
homogenized in 5 mM TCEP, fractionated into microsomes, labeled, and subjected to LC-
MS/MS analysis as described in Experimental Procedures. Approximately 6% of all 
cysteine-containing peptides from both the kidney and liver samples were modified with 
d6-dimedone suggesting that some sulfenylated cysteines may have been inaccessible to 
the TCEP reducing agent (Fig. 35). Also, the fractionation and labeling protocol may have 
introduced a slightly oxidative environment that modified highly susceptible cysteines. 
Nevertheless, this experiment serves as a control for the positive results. 
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Figure 35. Reduced Lysate Control Experiment of Human Microsomes. Kidney and 
liver tissue were homogenized in 5 mM TCEP, fractionated into microsomes, labeled, and 
subjected to LC-MS/MS analysis as described in Experimental Procedures. The number 
of d6-dimedone-labeled cysteine-containing peptides was taken as a percentage of total 
cysteine-containing peptides identified at 5% FDR. Reduced lysate control samples were 
acquired using a 30-minute gradient. 
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Four drug metabolizing P450s were chosen for more in-depth oxidative inhibition 
studies. Interestingly, P450 1A2 was resistant to oxidation, as established by spectral, 
inhibition, and dimedone labeling studies (Figs. 31A, 32A, and 33A, respectively). Of note 
was the hyperoxidation of Cys-159, which did not affect the catalytic activity of P450 1A2 
(Fig. 33A). This ancillary cysteine is positioned away from the active site, and its 
modification has a negligible effect on function (Fig. 36A). The resistance to oxidation is 
proposed to be related to access of oxidants or to stabilization of the heme-thiol system 
due to either the surrounding amino acid residues or the overall structure of the protein. 
This resistance may also allow for P450 1A2 to have such a high degree of enzymatic 
uncoupling and production of H2O2 when compared to other P450s (Table 3).   
P450 2C8 showed an 87% loss of catalytic activity at 1 mM H2O2, compared to the 
reduced control (Fig. 32B). This inhibition may seem surprising in light of the large number 
of cysteines contained in P450 2C8 (Fig. 37), but the heme thiol peptide was still modified. 
Despite the gradual loss of activity, the spectral and ICDID labeling studies (Figs. 31B and 
33B) showed a high loss and recovery of the heme-thiol ligand spectrally and significant 
sulfenic acid labeling (Cys-435). Only four of the 16 thiols were quantified because of the 
clustering of thiols in the sequence; i.e., some tryptic peptides contained up to four 
cysteines and spanned >25 amino acids.                                                          
            P450 2D6 showed less loss of activity (70%) than P450 2C8 but still exhibited 
inhibition after treatment with H2O2 (Fig. 32C) and the ability of the heme-thiol to re-ligand 
the heme iron in the spectral analysis (Fig 31C). This diminished response was reflected 
in ICDID analysis, which showed lower amounts of sulfenylation of the heme-thiol Cys-
443 and also Cys-191 (Fig. 33C).  
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Figure 36. Crystal Structure of P450s Highlighting Positions of Cysteine. Crystal 
structures for 1A2 (A), 2C8 (B), 2D6 (C), and 3A4 (D) were adapted from the RCSB Protein 
Data Bank (rcsb.org). The Accession numbers used were 2HI4, 2NNJ, 5TFT, and 5G5J, 
respectively. 
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Oxidized P450 3A4 showed an inability of the heme-thiol to re-ligand to the heme-
iron (after dithionite reduction), as judged by the spectra (Fig. 31D). This irreversible 
inactivation is proposed to be related to stabilization of the oxidized thiol by surrounding 
residues and is a unique feature among P450s tested. ICDID labeling showed high 
amounts of sulfenylation on several cysteine thiols, including the heme-thiol Cys-442, 
indicating a high susceptibility to oxidation. This sensitivity of the non-heme thiols can be 
considered in light of the report that a cysteine-depleted variant of P450 3A4 has increased 
activity compared to the wild-type enzyme (113). We concur that the cysteine residues are 
not essential but that the presence of the (non-heme peptide) sulfenic acids appears to be 
inhibitory to catalytic activity, through an unknown mechanism. 
There has been difficulty designing probes that can directly measure local bursts 
of H2O2 and not just a cumulative or average amount over time, especially in prominent 
production areas such as the plasma membrane, endoplasmic reticulum, and 
peroxisomes (237). When looking at redox issues, one mainly focuses on a concentration 
of H2O2 for which the effect can be reversed. This is the case for three of the four P450s 
tested spectrally, suggesting that this treatment does not irreversibly destroy the protein. 
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Figure 37. Number of Cysteines Found in Human P450 Enzymes. Cysteines of P450 
sequences obtained from Uniprot (uniport.org) were counted. The average number of 
cysteines in the human proteome (49) was applied to the average length of human P450s 
(501 amino acids) to determine the expected number of cysteines to be 11.3 (dotted 
vertical line).  
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These spectral studies have been challenging to interpret because the proper 
conditions have not yet been identified to produce a homogenous sample of stable 
sulfenylated heme-thiol cysteine P450 protein in large quantities. The spectral studies in 
conjunction, with the observation that sulfenylated cysteines cause enzymatic inhibition, 
lead us to believe this phenomenon is blocking steps in the P450 catalytic cycle. This 
blocked step may be reduction of the heme iron. This could be occurring directly (most 
likely) or through a peripheral oxidation that limits reductase binding. It may also reduce 
the ability for the heme iron to bind oxygen (or carbon monoxide in the case of the 
inhibitory or spectral studies, respectively).  The spectral studies also require physical 
changes (i.e., vacuum and slight bubbling) to remove the existing oxygen in the sample. 
These manipulation conditions likely affect some protein irreversibly, accounting at least 
in part for the cytochrome P420 seen in the pre-reduced samples. What is most relevant 
is the change in the amount of P450 seen between the reductase- and dithionite -reduced 
spectra (Fig. 31). 
It has been known that some P450s can catalyze reactions with the use of H2O2 
alone for quite some time (238-241). Also, mutating residues around the proximal heme 
ligand allows for alterations in both the heme redox potential and reactivity (242). P450s 
are also known to produce H2O2 as a byproduct of catalysis (32). CYP4A11 H2O2 
production was measured to be 5 µM min-1, which would be 25 nmol H2O2 min-1 under our 
experimental conditions (112). Typical incubation times would likely not produce enough 
H2O2 to produce an inhibitory effect. These data point to the significance of H2O2 in the 
catalytic cycle of P450s and of the residues surrounding the heme-thiol ligand. The 
presence of a biological mechanism that limits potentially harmful H2O2 shunting in certain 
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mammalian P450s but is not present in others (e.g. P450 1A2), seems reasonable but 
more studies are needed to evaluate the significance of this phenomenon.  
Our finding of both thiol-sensitive and insensitive P450s expands the knowledge 
of potential post-translational modifications found in drug metabolizing enzymes. In 
general, cysteines are reactive, underrepresented in the proteome, and conserved among 
proteomes (243). In an accounting of all human P450s, the number of cysteines varies 
from two to 15 (Fig. 37). Using the average length of all human P450s (501 amino acids) 
and the overall percent of cysteines found in the human proteome (2.3% (243)), the 
expected number of cysteines in human P450s would be 11.  Due to the deviation from 
this number, these cysteines may play important roles other than heme coordination and 
further investigation in cellular systems may be of interest.  
The drug metabolizing enzymes found to be sulfenylated in our proteomic screen 
and the subsequent validation of the inhibitory nature of this oxidative modification in 
P450s pose many new questions and potentially provide insight into the biological 
regulation of P450s. In further studies, a major goal is to determine the biological role of 
heme-thiolate sulfenylation and its relevance to oxidative stress. 
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Chapter V 
5. Conclusions and Future Directions 
5.1. A New Model of P450 Regulation 
Using methods, I developed which are outlined in Chapter II, I was able to propose 
a mechanism of oxidative inhibition in most P450s discussed in Chapters III and IV. This 
method centers around the concept that sulfenylation can occur on the heme-thiolate 
cysteine of the enzyme (Fig. 6). This phenomenon was observed in P450s 2C8, 2D6, 3A4, 
and 4A11 but not P450 1A2. Although this idea had been proposed by Hrycay and O’Brien 
in the 1970s, it was never tested to my knowledge (84).  
ICDID labeling of human and mouse liver and kidney microsomes revealed that 
many P450s and other drug metabolizing enzymes are sulfenylated. This finding, as well 
as in vitro results with recombinant enzymes, warrants further investigation. Determining 
how sulfenylation plays a role in drug metabolism in vivo may be important an important 
discovery because of the known interplay between drug AUCs and inflammatory diseases 
where an increase in ROS leads to longer drug half-lives(118). This question is difficult to 
answer because of the pleiotropic effects ROS have in cells. Targeting P450 enzymes 
directly with a specific form of oxidant (i.e. ROS) would be extremely difficult, and proper 
controls would have to be in place for meaningful results.  
One of the more important questions is how would oxidation of some P450 
enzymes confer a biological advantage through heme-thiolate sulfenylation? There are 
currently several theories postulated:  
(1) Limitation of futile cycling. Without substrate present P450 enzymes are still 
able to be reduced allowing the ferrous heme to bind oxygen. The activated oxygen will 
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likely be released as superoxide if no substrate is present. The heme-thiolate ligand 
provides sufficient electronegativity to allow for this oxygen binding, by attracting electron 
density to the thiolate cysteine. It follows then, that the lack of this fifth ligand would prevent 
oxygen binding. This could be beneficial for the cell because it limits oxygen and NADPH 
consumption while reducing the amount of harmful ROS produced. This theory could be 
tested in cells (primary hepatocytes) by examining the amount of heme-thiolate 
sulfenylation present in P450s with or without substrate available. If this theory were 
proven, then presumably, sulfenylation would be high before adding substrate. After 
incubation of cells with substrate, a decrease in heme-thiolate sulfenylation would be 
correlative with enzymatic activity.  
(2) Inactivation during an oxidative insult. In times of oxidative stress, cells require 
reducing equivalents in the forms of GSH and NAD(P)H to counteract and survive the 
stress. P450s that are mainly xenobiotic metabolizing enzymes (e.g. P450s 3A4 and 2D6) 
are not necessary for survival and can therefore be inactivated until the redox environment 
reaches homeostasis. This would allow NADPH to be diverted to enzymes devoted to 
combating oxidative stress, e.g. glutathione reductase and thioredoxin reductase. Testing 
this hypothesis would involve exposing cells (primary hepatocytes) to an oxidative insult 
such as paraquat or H2O2 and measuring the enzymatic activity, sulfenylation, and NADPH 
levels. In this case, a decrease in NADPH levels would lead to a loss in enzymatic activity 
and a concomitant increase in heme-thiolate sulfenylation would be observed.  
(3) Oxidative modification as a degradation signal. Oxidation of cysteine thiols has 
been shown to signal proteins for degradation. This is likely a protective mechanism as 
oxidation can modify other amino acids, inactivating proteins. Since cysteines are the most 
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easily oxidized amino acids in proteins, this process serves as a chemosensor for 
damage. Downregulation of P450s due as response to inflammation has been reported 
(118). Oxidation of thiols of P450s may be an acute response to inflammatory insults. With 
the goal of removing (in)active P450 enzyme before P450 genes are transcriptionally 
downregulated. To test this hypothesis, a proteasome inhibitor such as carfilzomib could 
be used in conjunction with an oxidative insult to cells (primary hepatocytes). Presumably 
a buildup of sulfenylated protein would be observed compared to the control sample with 
no oxidative stress.  
(4) Another reason for this modification would be the one originally proposed by 
Hrycay and O’Brien (110). They postulated that formation of a sulfenic acid on the heme-
thiolate ligand would alter the spin state of the iron, allowing the enzyme to more easily 
catalyze peroxidatic reactions with H2O2 being a co-substrate, donating oxygen. This could 
be possible because P450 enzymes can utilize oxygen from peroxides and peracids as 
co-substrates. During oxidative stress events, highly reactive lipid peroxides and 
isoprostanes are produced. This P450 sulfenylation may allow for more facile metabolism 
of these damaging oxidative byproducts. This can be first tested in vitro by oxidizing 
recombinant P450, removing H2O2 and adding an organic peroxide such as cumene-
peroxide with a peroxidatic substrate such as N, N, N’, N’, tetramethyl-p-
phenylenediamine. This would provide a spectroscopic signal to measure the relative 
activities of oxidized and reduced protein. Testing this hypothesis in cells would be 
markedly more difficult. Using a cell line devoid of P450 expression, P450 enzymes (and 
reductase if necessary) could be stably transfected and the amount of total peroxides or 
113 
 
isoprostanes could be measured after an oxidative insult. This measurement of peroxides 
in conjunction with sulfenylation could verify that this mechanism is possible.  
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Figure 38. Sequence Alignment of Surrounding Heme-thiolate Amino Acids. 
Alignment of P450s tested (Top). Probability matrix of amino acids surrounding the heme-
thiolate ligand generated from sequences of all 57 human P450s (Bottom). Bottom matrix 
generated through WebLogo (244). 
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5.2. P450s Have Three Classes of Redox Sensitivity 
As mentioned in Chapter IV, P450 enzymes seem to fall into three classes 
following oxidative stress: (1) Redox Insensitive (1A2), (2) heme-thiolate sensitive (2C8, 
2D6, 4A11), and (3) ancillary thiol sensitive (3A4). These results were a surprising 
discovery. From the proteomic screen of sulfenylation in human liver and kidney 
microsomes (Table 5), I hypothesized that all P450s would share a similar sensitivity to 
H2O2. However, in vitro results with recombinant enzymes show that this is not the case.  
Regarding heme-thiolate sulfenylation, I believe the differences in susceptibility 
observed arise from a combination of several factors. From only testing five P450s thus 
far, data is limited for general inferences. However, there are differences in the amino acid 
sequence surrounding the heme-thiolate cysteine (Fig. 38). P450 1A2 has three positive 
charges in close proximity to the cysteine ligand possibly adding a stabilizing the thiol-iron 
interaction. This surrounding amino acid sequence is known to favor the stability of the 
thiolate coordination to the heme iron. The known consensus sequence for the heme 
thiolate cysteine is Phe-x-x-Gly-x-Arg-x-Cys-x-Gly (245). As “x” indicates a variable amino 
acid, this region is not well conserved and there are likely differences in the strength and 
stability of the heme-thiolate ligand among P450s (Fig. 38). These potential disparities 
among P450s could lead to differences in liganding ability of the thiol to the heme-iron 
yielding breakage of the thiol-iron coordination and exposing the thiol to potential oxidation 
by H2O2.This may happen more frequently with P450 4A11 (and other Subfamily 4A 
P450s), because the heme is covalently linked to the protein. Therefore, movement of the 
heme would be more limited than if it were free, potentially allowing the heme-thiol to 
recoordinate without having to “find” the iron. This heme thiolate coordination is much 
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likely weaker when the sixth ligand is water coordinated to ferric heme compared to 
molecular oxygen or CO bound to ferrous heme. This ferrous bound form has much higher 
electronegativity which pulls the thiolate closer, strengthening the bond.  
Ancillary cysteines are likely to have surrounding microenvironments that stabilize 
the thiolate and allow for interaction with ROS such as H2O2. Oxidation of these cysteines 
may disrupt the P450 interaction with its substrate or redox partner, inhibiting its catalytic 
activity. 
5.3.  Future Directions  
There are five major questions that need to be addressed to increase the 
understanding of H2O2-dependent inhibition of P450s through sulfenic acid formation of 
the heme-thiolate ligand:  
(1) How do other P450 enzymes respond to H2O2 preincubation? As noted 
previously in Section 5.2, the results I have acquired are limited in consideration of the 
number of P450 enzymes currently known. By measuring redox sensitivity of more 
enzymes, we should be able to build an inference model to predict enzyme sensitivity. 
This could be a powerful tool that one could use to putatively predict redox classes of 
P450s without testing them in vitro.  
(2) Is this modification biologically relevant and, if so, what is the function of this 
modification? Biological relevance of a posttranslational modification on an amino acid 
required for catalytic activity is inherently difficult to test because, in this case, the cysteine 
cannot be mutated without compromising the enzyme. I have highlighted several possible 
biological reasons for heme-thiolate sulfenylation in Section 5.1, and testing these in 
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primary hepatocytes would provide a biological context and give more insight into the 
biological mechanism of the modification.  
(3) Is heme-thiolate sulfenylation reversible enzymatically in vitro and in vivo? 
Results from studies with microsomes (in situ) indicate that this modification likely occurs 
in vivo. Since sulfenic acids can easily be further oxidized to sulfonic acids or disulfide 
bonds a mechanism likely exists to reduce the sulfenic acid to a thiolate, allowing for 
recoordination with the heme iron. This can be performed using classical biochemical 
methods, e.g. preincubating the P450 with H2O2 and adding back both active and inactive 
(heat treated) cytosolic and microsomal cellular fractions. Reversibility could be measured 
by a cellular fraction concentration-dependent increase in activity relative to the control. 
Reversibility could then be followed through chromatographic separations of either the 
cytosol or microsomes. Finally, proteomic analysis followed by recombinant expression of 
candidate proteins could be utilized to determine the protein with the reversible activity.  
(4) How stable is the heme-thiolate sulfenic acid? From my experiments, it seems 
that the sulfenic acid is stable enough to survive through several manipulations (e.g. 
preparation of microsomes, and in vitro spectroscopic and activity assays), but the 
mechanism behind this stability is not known. Molecular dynamics (MD) simulations of 
P450 with a heme-thiolate sulfenic acid present may provide some insight into this 
phenomenon. Using the knowledge gained from MD, mutations could be made to the 
enzyme and tested in vitro for either resistance or susceptibility to redox modification. 
These experiments, in conjunction with question (1), can help define the amino acids 
required for sulfenic acid formation and stability.  
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(5) How are the electronics of the heme-iron affected by heme-thiolate sulfenylation? 
Understanding the changes conferred to the heme iron by sulfenic acid formation would 
help to further understand the catalytic competency of the oxidized enzyme. There are 
some limitations in studying this, however. Instruments to study this type of electronic 
change to the iron such as Mössbauer spectroscopy or electron paramagnetic resonance 
(EPR) require large quantities of homogenously oxidized protein in high concentration. 
Currently I have not been able to oxidize high concentrations of P450 consistently. The 
main issue with producing homogenously oxidized P450 is the concern that the oxidation 
will aggregate the protein at high concentrations.  
 
In summary, a novel oxidative regulatory method for P450 enzymes has been 
discovered. By showing that P450s have differential sensitivity to H2O2, I have raised more 
questions than I currently have answers for in the field of drug metabolism. I hope that 
determining the in vivo relevance of heme-thiolate sulfenylation will help to provide more 
context in the future.  
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APPENDIX 
Figure A1. Representative MS/MS Spectra of P450 recombinant 1A2. Some annotated 
spectra produced by protein prospector MS-Product 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct) 
Cys158-containing peptide alkylated with d0-dimedone 
LAQNALNTFSIASDPASSSSC*YLEEHVSK (Light) 
 
Cys158-containing peptide alkylated with d6-dimedone 
LAQNALNTFSIASDPASSSSC*YLEEHVSK (Heavy) 
 
 
 
138 
 
Representative XIC peaks integrated for Cys158-containing peptide: 
 
Cys457-containing peptide alkylated with d0-dimedone 
C*IGEVLAK (Light) 
 
 
 
 
 
 
 
139 
 
Cys457-containing peptide alkylated with d6-dimedone 
C*IGEVLAK (Heavy) 
 
Representative XIC peaks integrated for Cys457-containing peptide: 
 
 
 
 
 
 
 
 
140 
 
Cys503-containing peptide alkylated with d0-dimedone 
C*EHVQAR (Light) 
 
Cys503-containing peptide alkylated with d6-dimedone 
C*EHVQAR (Heavy) 
 
 
 
 
 
141 
 
Representative XIC peaks integrated for Cys503-containing peptide: 
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Figure A2. Representative MS/MS Spectra of P450 recombinant 2C8. Some annotated 
spectra produced by protein prospector MS-Product 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct) 
Cys50-containing peptide alkylated with d0-dimedone 
DIC*K (Light) 
 
 
Cys50-containing peptide alkylated with d6-dimedone 
DIC*K (Heavy) 
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Representative XIC peaks integrated for Cys50-containing peptide: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
Cys149-containing peptide alkylated with d0-dimedone 
VQEEAHC*LVEELR (Light)
 
Cys149-containing peptide alkylated with d6-dimedone 
VQEEAHC*LVEELR (Heavy) 
 
 
 
 
 
145 
 
Representative XIC peaks integrated for Cys151-containing peptide: 
 
Cys264-containing peptide alkylated with d0-dimedone 
DFIDC*FLIK (Light) 
 
 
 
 
 
 
146 
 
Cys264-containing peptide alkylated with d6-dimedone 
DFIDC*FLIK (Heavy) 
 
Representative XIC peaks integrated for Cys264-containing peptide: 
 
 
 
 
 
 
 
147 
 
Cys337-containing peptide alkylated with d0-dimedone 
SPC*MQDR (Light) 
 
Cys337-containing peptide alkylated with d6-dimedone 
SPC*MQDR (Heavy) 
 
 
 
 
148 
 
Representative XIC peaks integrated for Cys338-containing peptide: 
 
Cys434-containing peptide alkylated with d0-dimedone 
IC*AGEGLAR (Light) 
 
 
 
 
 
149 
 
Cys434-containing peptide alkylated with d6-dimedone 
IC*AGEGLAR (Heavy) 
 
Representative XIC peaks integrated for Cys434-containing peptide: 
 
 
 
 
 
150 
 
Figure A3. Representative MS/MS Spectra of P450 recombinant 2D6. Some annotated 
spectra produced by protein prospector MS-Product 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct) 
Cys190-containing peptide alkylated with d0-dimedone 
AVSNVIASLTC*GR (Light) 
 
Cys190-containing peptide alkylated with d6-dimedone 
AVSNVIASLTC*GR (Heavy) 
 
 
 
151 
 
Representative XIC peaks integrated for Cys190-containing peptide: 
 
Cys442-containing peptide alkylated with d0-dimedone 
AC*LGEPLAR (Light) 
 
 
 
 
 
 
152 
 
Cys442-containing peptide alkylated with d6-dimedone 
AC*LGEPLAR (Heavy) 
 
Representative XIC peaks integrated for Cys443-containing peptide: 
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Figure A4. Representative MS/MS Spectra of P450 recombinant 3A4. Some annotated 
spectra produced by protein prospector MS-Product 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct) 
Cys96-containing peptide alkylated with d0-dimedone 
EC*YSVFTNR (Light) 
 
Cys96-containing peptide alkylated with d6-dimedone 
EC*YSVFTNR (Heavy) 
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Representative XIC peaks integrated for Cys98-containing peptide: 
 
Cys376-containing peptide alkylated with d0-dimedone 
LERVC*K (Light) 
 
 
 
 
 
 
155 
 
Cys376-containing peptide alkylated with d6-dimedone 
LERVC*K (Heavy) 
 
Representative XIC peaks integrated for Cys376-containing peptide: 
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Cys440-containing peptide alkylated with d0-dimedone 
NC*IGMR (Light) 
 
Cys440-containing peptide alkylated with d6-dimedone 
NC*IGMR (Heavy) 
 
 
 
157 
 
Representative XIC peaks integrated for Cys440-containing peptide: 
 
Cys467-containing peptide alkylated with d0-dimedone 
VLQNFSFKPC*K (Light) 
 
 
 
 
 
 
158 
 
Cys467-containing peptide alkylated with d6-dimedone 
VLQNFSFKPC*K (Heavy) 
 
Representative XIC peaks integrated for Cys467-containing peptide: 
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Figure A5. Hyperoxidation of P450 3A4 Cys467. MS/MS Spectra of hyperoxidized Cys-
467 
VLQNFSFKPC(SO2)K 
 
VLQNFSFKPC(SO3)K 
 
 
 
